{"study_id": 55964, "supplement_id": 1110, "safety_score": "70", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to review the stability, biological activity, and degradation kinetics of EGCG in different conditions and assess methods to enhance its stability for clinical use.", "results_summary": "EGCG shows promising antioxidant and gene-regulatory effects in cell cultures but limited efficacy in animal and human studies due to low stability and bioavailability. Stabilizers and encapsulation methods can improve its stability and activity.", "population_specificity": "Not specified (review of existing studies).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:43.159351+00:00"}
{"study_id": 55962, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to examine the efficacy of green tea extract (GTE) high in epigallocatechin gallate (EGCG) on blood lipid profiles in healthy postmenopausal women.", "results_summary": "GTE supplementation significantly reduced total cholesterol, LDL cholesterol, and non-HDL cholesterol but increased triglycerides, particularly in obese women and statin users. No effect was observed on HDL cholesterol.", "population_specificity": "Healthy postmenopausal women, stratified by COMT genotype activity.", "effective_dosage": "4 capsules daily (1315 mg catechins, including 843 mg EGCG).", "study_duration": "12 months.", "interactions": "Potential interaction with statins noted (increased triglycerides in statin users).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:43.301360+00:00"}
{"study_id": 55958, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess whether Epigallocatechin Gallate (EGCG) could extend the therapeutic window of rt-PA treatment in stroke patients.", "results_summary": "EGCG significantly improved treatment outcomes in patients with delayed onset-to-treatment time, as shown by improved NIHSS scores, likely due to reduced plasma levels of MMP-2 and MMP-9. Strong correlations were found between MMP levels and NIHSS scores.", "population_specificity": "Stroke patients receiving rt-PA treatment, particularly those with delayed onset-to-treatment time.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:43.443912+00:00"}
{"study_id": 55959, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of Epigallocatechin Gallate (EGCG) as an anti-influenza agent, focusing on its inhibitory effects on influenza viruses and its ability to overcome drug-resistant mutations.", "results_summary": "EGCG demonstrated inhibitory effects on influenza A and B viruses in vitro and showed neuraminidase inhibitory activity, suggesting potential to counteract drug-resistant strains. The study also highlighted the promise of chemically modified catechin derivatives for future antiviral drug development.", "population_specificity": "Madin-Darby canine kidney cells (in vitro study).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:44.012576+00:00"}
{"study_id": 55965, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the anticancer effects of Epigallocatechin Gallate (EGCG) in combination with other polyphenols and micronutrients, focusing on its ability to inhibit tumor growth, metastasis, and other cancer-related processes.", "results_summary": "The study found that EGCG, when combined with other polyphenols and micronutrients, significantly inhibited cancer cell proliferation, tumor growth, metastasis, and MMP secretion, while also inducing apoptosis. The presence of vitamin C, amino acids, and other micronutrients enhanced EGCG's inhibitory effects on MMP secretion.", "population_specificity": "Cancer cell lines (Fanconi anemia head and neck squamous cell carcinoma, fibrosarcoma HT-1080, melanoma A2058, ovarian cancer ES-2 xenograft, and ovarian cancer A-2780 cells) and in vivo models.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:44.227703+00:00"}
{"study_id": 55967, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of Epigallocatechin Gallate (EGCG) as a nutraceutical targeting androgen receptor signaling for the prevention and treatment of prostate cancer.", "results_summary": "The study suggests that EGCG, along with other nutraceuticals, targets multiple pathophysiological mechanisms in prostate cancer, including AR signaling, and may inhibit cancer growth and metastatic progression due to its multi-targeting properties and lower systemic toxicity.", "population_specificity": "Men with prostate cancer, particularly those with hormone-refractory disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:51.191149+00:00"}
{"study_id": 55971, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to discuss EGCG's anti-cancer activity and review nanotechnology strategies to enhance its properties for cancer therapy.", "results_summary": "EGCG shows promising anti-cancer activity and synergizes with common anti-cancer agents, but its clinical application is limited by stability and bioavailability issues. Nanotechnology may improve EGCG's pharmacokinetics and pharmacodynamics for better anti-tumoral effects.", "population_specificity": "Not specified (general discussion, not a clinical trial)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:51.394070+00:00"}
{"study_id": 55969, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to summarize the molecular interactions, biophysical effects, and therapeutic potential of Epigallocatechin Gallate (EGCg), focusing on its antioxidant properties, impact on cell behavior, and applications in treating illnesses.", "results_summary": "The study found that EGCg exhibits antioxidant properties and affects cell adhesion, motility, migration, stiffness, apoptosis, and proliferation, with differential impacts on normal and cancer cells. It also highlighted potential therapeutic uses, such as combining EGCg with nanoparticles or anticancer compounds to enhance effects.", "population_specificity": "Various cell lines, animal models, microbes, and clinical trials (not specified in detail).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:52.386539+00:00"}
{"study_id": 55968, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether green tea polyphenols (GTP), specifically epigallocatechin gallate, could reduce residual albuminuria in diabetic patients with nephropathy despite maximum RAS inhibition.", "results_summary": "GTP administration reduced urinary albumin-creatinine ratio (UACR) by 41% compared to a 2% increase in the placebo group, with significant reductions in podocyte apoptosis and albumin permeability, suggesting a protective effect on kidney function.", "population_specificity": "42 diabetic subjects (17 type 2, 4 type 1) with UACR >30 mg/g despite maximum RAS inhibition.", "effective_dosage": "800 mg epigallocatechin gallate daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:52.536050+00:00"}
{"study_id": 55972, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to compare the anti-inflammatory effects of epigallocatechin gallate (EGCG) against prednisolone across multiple inflammatory pathways.", "results_summary": "EGCG demonstrated strong anti-inflammatory effects comparable to prednisolone in assays measuring TNF-\u03b1, IL-6, IL-8 expression, ROS production, and platelet activation, identifying it as a potential alternative to glucocorticoids.", "population_specificity": "In vitro assays using macrophages, colon epithelial cells, polymorphonuclear leukocytes, and whole blood.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:52.695092+00:00"}
{"study_id": 55970, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to summarize clinical evidence on the benefits of phytochemicals, including Epigallocatechin Gallate, as adjuvant therapy alongside conventional anticancer treatments.", "results_summary": "The study found that Epigallocatechin Gallate has significant alleviative effects on chemotherapy-induced toxicities, though direct anticancer activity was not specifically highlighted for this compound.", "population_specificity": "Patients with various types of cancer, including hepatocarcinoma, prostate cancer, leukemia, lymphoma, breast and ovarian cancer, and gastrointestinal cancers.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:52.757912+00:00"}
{"study_id": 55966, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of oxidative stress in early-onset myopathies and evaluate the potential of epigallocatechin gallate (EGCG) as a therapeutic antioxidant for Duchenne Muscular Dystrophy (DMD).", "results_summary": "The abstract indicates that EGCG is being tested in clinical trials for DMD, following preclinical success in correcting the phenotype in cell or animal models, suggesting it may help mitigate oxidative stress as a secondary pathophysiological mechanism.", "population_specificity": "Patients with Duchenne Muscular Dystrophy (DMD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:54.218996+00:00"}
{"study_id": 55973, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine whether a decaffeinated green tea extract (GTE) standardized for EGCG content could reduce acne lesions in women with post-adolescent acne.", "results_summary": "The study found significant reductions in inflammatory lesions on the nose, perioral area, and chin in the GTE group compared to placebo. Within the GTE group, there were also significant reductions in lesions on the forehead and cheeks, as well as total lesion counts and total cholesterol levels.", "population_specificity": "Women aged 25-45 with moderate-to-severe post-adolescent acne.", "effective_dosage": "1500 mg of decaffeinated GTE daily (providing 856 mg EGCG).", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:45:56.139374+00:00"}
{"study_id": 55975, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether the combination of cysteamine and epigallocatechin gallate (EGCG) could restore CFTR function and reduce lung inflammation in patients with specific CFTR mutations.", "results_summary": "The combination treatment improved CFTR function, reduced inflammation, and restored autophagy in nasal cells, particularly in patients with Phe508del mutations. However, some patients with other CFTR mutations did not respond to the therapy.", "population_specificity": "Patients with cystic fibrosis homozygous or heterozygous for Phe508del CFTR mutations, as well as some with other class II CFTR mutations.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:00.340075+00:00"}
{"study_id": 55976, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and potential disease-modifying effects of Epigallocatechin-gallate in patients with multiple system atrophy (MSA) over 48 weeks.", "results_summary": "The study provides a rationale for investigating Epigallocatechin-gallate's ability to delay MSA-related disability progression, with power calculations suggesting a 50% effect size for efficacy compared to placebo. No specific results on outcomes are detailed in the abstract.", "population_specificity": "Patients with multiple system atrophy (MSA).", "effective_dosage": "Not specified", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:01.010729+00:00"}
{"study_id": 55978, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the interplay between traditional herbs with low bioavailability (including polyphenols like Epigallocatechin Gallate) and gut microbiota, focusing on health promotion and disease prevention mechanisms.", "results_summary": "The study found that traditional herbs, including those with polyphenols, could influence gut microbiota structure and undergo gut microbiota-mediated bioconversion to exert therapeutic effects, though specific findings on Epigallocatechin Gallate were not detailed.", "population_specificity": "Not specified (general focus on preclinical and clinical studies involving herb-microbiota interactions).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:01.392446+00:00"}
{"study_id": 55980, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the potential of Epigallocatechin Gallate (EGCG) as an adjuvant therapy to improve therapeutic benefits in pediatric cancer treatment.", "results_summary": "The abstract highlights EGCG as a promising natural compound with excellent results in vitro and in vivo, suggesting its potential use in combination with standard therapeutic protocols. However, specific results regarding EGCG's efficacy or mechanisms are not detailed.", "population_specificity": "Pediatric cancer patients (implied, not explicitly stated).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:01.466015+00:00"}
{"study_id": 55974, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine whether green tea supplementation, specifically Epigallocatechin Gallate, induces changes in the composition of the human gut microbiota over 12 weeks.", "results_summary": "The study found no significant changes in gut microbiota composition, bacterial diversity, or body composition in subjects receiving green tea capsules compared to placebo. Overweight subjects showed reduced bacterial alpha diversity compared to normal-weight subjects, but green tea supplementation did not significantly alter this outcome.", "population_specificity": "58 Caucasian men and women, including both normal-weight and overweight individuals.", "effective_dosage": ">0.56 g/d Epigallocatechin Gallate + 0.28\u20130.45 g/d caffeine.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:01.740058+00:00"}
{"study_id": 55979, "supplement_id": 1110, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of MD2011001 cream, containing epigallocatechin gallate, for treating mild-to-moderate atopic dermatitis in sensitive facial and neck areas.", "results_summary": "The study found a statistically significant reduction in IGA scores and faster improvement in affected surface area with MD2011001 compared to placebo, with a favorable safety profile and local tolerance.", "population_specificity": "Patients with mild-to-moderate atopic dermatitis (IGA score 2 or 3) affecting the face, perioral/periocular area, and/or neck (44 participants: 29 female, 15 male).", "effective_dosage": "Not specified", "study_duration": "28 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:01.837613+00:00"}
{"study_id": 55981, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to review the potential of Epigallocatechin Gallate (EGCG) and other nutraceuticals for Alzheimer's disease prevention and treatment, focusing on its antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing effects.", "results_summary": "The abstract suggests that EGCG exhibits antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing properties, which may help delay Alzheimer's disease onset or slow its progression. However, specific results for EGCG alone are not detailed.", "population_specificity": "Not specified (general review of potential effects for Alzheimer's disease patients).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:03.691968+00:00"}
{"study_id": 55985, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to review the biological effects of polyphenols, including Epigallocatechin Gallate, focusing on their potential to prevent and treat diseases like cancer and neurodegenerative disorders.", "results_summary": "The study highlights Epigallocatechin Gallate's ability to neutralize reactive oxygen species (ROS) and modulate cell signaling pathways like MAP kinase, suggesting potential preventative and adjunct therapeutic roles in malignancies.", "population_specificity": "Not specified (general review of polyphenols' effects).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:09.184456+00:00"}
{"study_id": 55987, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the chemopreventive and anti-cancer potential of Epigallocatechin Gallate in breast cancer treatment.", "results_summary": "The study found that Epigallocatechin Gallate exhibits anti-cancer properties by regulating antioxidant enzyme activities and inducing antiproliferative and apoptotic effects in breast cancer cell lines. It highlights its potential as a therapeutic agent for breast cancer.", "population_specificity": "Breast cancer cell lines (in vitro study).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:09.526405+00:00"}
{"study_id": 55984, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effect of daily green tea extract (containing Epigallocatechin Gallate) consumption on biomarkers of breast cancer risk in high-risk postmenopausal women.", "results_summary": "The abstract describes the study design and participant characteristics but does not report specific results on the effects of Epigallocatechin Gallate on the primary or secondary endpoints.", "population_specificity": "Healthy postmenopausal women at high risk of breast cancer due to dense breast tissue, stratified by COMT genotype activity.", "effective_dosage": "843.0 \u00b1 44.0 mg/day Epigallocatechin Gallate", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:09.793929+00:00"}
{"study_id": 55986, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to review the potential therapeutic role of EGCG in health and disease, focusing on its antioxidant, antitumor, anti-Alzheimer, and anti-aging properties.", "results_summary": "The study suggests EGCG has significant antioxidant properties, potentially preventing tissue-level oxidative damage and offering benefits in conditions like cancer, Alzheimer's, and aging. However, the abstract does not provide specific clinical outcomes or statistical evidence.", "population_specificity": "Not specified (general review of existing evidence).", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:09.795555+00:00"}
{"study_id": 55988, "supplement_id": 1110, "safety_score": "95", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to examine the effect and safety of high-dose green tea extract (EGCG) on weight reduction, lipid profile changes, and obesity-related hormone peptides in women with central obesity.", "results_summary": "The study found significant weight loss, reduced waist circumference, and decreased total cholesterol and LDL levels after 12 weeks of high-dose EGCG treatment, with no reported side effects. Elevated adiponectin and lower ghrelin levels were also observed in the treatment group.", "population_specificity": "Women with central obesity (BMI \u2265 27 kg/m\u00b2 and waist circumference \u2265 80 cm).", "effective_dosage": "856.8 mg daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:10.697501+00:00"}
{"study_id": 55983, "supplement_id": 1110, "safety_score": "30", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to assess the safety and neuroprotective effects of Polyphenon E (containing Epigallocatechin Gallate) in people with multiple sclerosis, and to correlate plasma EGCG levels with neuroprotective outcomes.", "results_summary": "Phase I showed a 10% increase in NAA levels, rejecting futility, with no serious adverse events. Phase II was halted due to abnormal liver function tests in most participants on Polyphenon E, preventing further efficacy analysis. EGCG plasma levels correlated with NAA changes when referenced to water content but not creatine.", "population_specificity": "People with relapsing-remitting or secondary progressive multiple sclerosis, stable on glatiramer acetate or interferon \u03b2 therapy.", "effective_dosage": "400 mg EGCG twice daily (total 800 mg/day).", "study_duration": "Phase I: 6 months; Phase II: intended 1 year (stopped early).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:11.242606+00:00"}
{"study_id": 55989, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore how epigallocatechin gallate (EGCG) triggers activation of ATM in cancer cells and its role in modulating DNA damage response and TRAIL-induced signaling.", "results_summary": "The study highlights that EGCG, among other phytochemicals, activates ATM in various cancer cells, potentially influencing DNA repair, cell cycle arrest, and apoptosis. It suggests EGCG may enhance the response to DNA damage-inducing therapies.", "population_specificity": "Cancer cells (in vitro studies)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:11.931354+00:00"}
{"study_id": 55982, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore novel nanoparticle-based delivery strategies to improve the stability, bioavailability, and target specificity of Epigallocatechin Gallate and other phytochemicals for cancer prevention and treatment.", "results_summary": "The study found that nanoparticle delivery systems can enhance the stability, solubility, absorption, and bioavailability of Epigallocatechin Gallate, improve its target specificity to cancer cells, and potentially reduce toxicity to normal tissues. These advancements may enhance its anti-cancer activities.", "population_specificity": "Not specified (general focus on cancer prevention/treatment applications).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:13.930400+00:00"}
{"study_id": 55990, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to review the potential role of green tea and its chief constituent, epigallocatechin gallate (EGCG), in cancer prevention and treatment through modulation of cell signaling pathways.", "results_summary": "The study found that green tea and EGCG have a potential role in managing cancer by modulating cell signaling pathways, acting as chemopreventive agents, and showing beneficial effects in cancer prevention and treatment.", "population_specificity": "Not specified (general review of existing studies)", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:16.933059+00:00"}
{"study_id": 55991, "supplement_id": 1110, "safety_score": "80", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate Epigallocatechin Gallate as a low-toxicity, broad-spectrum antiinflammatory agent targeting multiple cancer-related pathways.", "results_summary": "The study suggests Epigallocatechin Gallate may simultaneously target multiple inflammatory pathways relevant to cancer, but specific efficacy data or clinical outcomes are not detailed in the abstract.", "population_specificity": "Not specified (general discussion of cancer-related inflammation).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:17.060824+00:00"}
{"study_id": 55992, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the potential protective effects of epigallocatechin gallate (EGCG) against cardiovascular calcification.", "results_summary": "The study found that EGCG, along with other antioxidant compounds like resveratrol, was protective against cardiovascular calcification, contrasting with the ineffectiveness of antioxidant vitamins.", "population_specificity": "Individuals at risk of cardiovascular calcification (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:17.249744+00:00"}
{"study_id": 55994, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the role of Epigallocatechin Gallate in inhibiting JAK/STAT signaling and IDO expression as a potential therapeutic strategy for cancer.", "results_summary": "The study suggests that Epigallocatechin Gallate, among other phytochemicals, can inhibit JAK/STAT signaling and IDO expression, potentially contributing to the inhibition of tumor proliferation and development.", "population_specificity": "Not specified (general cancer-related mechanisms discussed).", "effective_dosage": "Not provided.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:18.618422+00:00"}
{"study_id": 55993, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to explore Epigallocatechin Gallate as a potential therapeutic agent targeting the tumor microenvironment for cancer prevention and treatment.", "results_summary": "The study identified Epigallocatechin Gallate as one of several natural products that may warrant further investigation for targeting the tumor microenvironment, suggesting its potential role in regulating tumorigenesis. No specific results on its efficacy were detailed in the abstract.", "population_specificity": "Not specified (general tumor microenvironment context)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:18.781189+00:00"}
{"study_id": 55995, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 60, "study_goal": "The researchers aimed to review preclinical and clinical evidence on the protective effects of dietary phenolics, including epigallocatechin gallate, against colorectal cancer.", "results_summary": "The abstract indicates that preclinical studies suggest anticancer effects of epigallocatechin gallate, but clinical evidence remains weak, with required doses exceeding typical dietary intake.", "population_specificity": "Patients with colorectal cancer or at risk (familial adenopolyposis or aberrant crypt foci).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:18.781907+00:00"}
{"study_id": 55996, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify Epigallocatechin Gallate (EGCG) as a potential natural compound for broad anti-angiogenic therapy in cancer treatment.", "results_summary": "EGCG was identified as one of 10 prototypical phytochemicals capable of inhibiting multiple aspects of tumor angiogenesis, with potential for use in combination therapies to enhance efficacy and reduce toxicity. The study suggests EGCG may positively impact other tumorigenic pathways, though specific efficacy data for EGCG alone were not detailed.", "population_specificity": "Not specified (theoretical analysis based on literature review).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:21.178097+00:00"}
{"study_id": 55997, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether green tea extract-enriched rye bread (GTRB), containing epigallocatechin gallate, could improve weight loss maintenance and metabolic syndrome-related abnormalities.", "results_summary": "GTRB did not significantly affect weight loss maintenance, HDL-cholesterol, triglycerides, or glucose levels but showed minor benefits in waist circumference reduction and better blood pressure control. The proportion of subjects meeting metabolic syndrome criteria was lower in the intervention group.", "population_specificity": "55 obese men and women (mean age 53.0\u00b17.0 years, BMI 35.0\u00b15.5 kg/m\u00b2).", "effective_dosage": "188.3 mg/day (women) and 242.1 mg/day (men) of epigallocatechin gallate, delivered via 280 g (women) or 360 g (men) of GTRB.", "study_duration": "12-week weight maintenance phase following an 8-week weight loss phase.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:24.831942+00:00"}
{"study_id": 55998, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to review plants and phytochemical compounds, including Epigallocatechin Gallate, for their beneficial effects against pancreatic cancer cells through multiple mechanisms.", "results_summary": "The study found that Epigallocatechin Gallate demonstrated beneficial action against pancreatic cancer cells through four or more mechanisms, suggesting potential as an efficient pharmacological agent.", "population_specificity": "Pancreatic cancer cells (in vitro and in vivo studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:25.381410+00:00"}
{"study_id": 56003, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention Epigallocatechin Gallate or its effects.", "results_summary": "The abstract does not discuss Epigallocatechin Gallate or its outcomes.", "population_specificity": "Not specified (abstract focuses on TTR amyloidosis treatments broadly).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:25.386848+00:00"}
{"study_id": 56002, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to summarize the potential of Epigallocatechin Gallate (EGCG) as an anticancer agent through AMPK activation.", "results_summary": "The study found that EGCG demonstrated tumor-inhibiting properties, primarily through activation of the AMPK/mTOR signaling pathway, similar to other non-classical drugs like metformin and aspirin.", "population_specificity": "Not specified (review of literature)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:26.251468+00:00"}
{"study_id": 55999, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether the sequential administration of epigallocatechin gallate (EGCG) could sustain the therapeutic effects of cysteamine in improving CFTR function and reducing inflammation in cystic fibrosis patients with the F508del-CFTR mutation.", "results_summary": "The study found that EGCG, when administered after cysteamine, sustained the improvement in CFTR function and reduced inflammation in both mice and human CF patients. The combination of cysteamine and EGCG restored autophagy markers and improved clinical outcomes, such as reduced chloride concentrations in sweat and lower inflammatory markers.", "population_specificity": "Newborn mice with the F508del-CFTR mutation and 10 F508del-CFTR homozygous cystic fibrosis patients.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:26.801480+00:00"}
{"study_id": 56000, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to review existing literature on EGCG's insulin-mimetic actions and its potential to ameliorate metabolic insulin resistance and endothelial dysfunction in type 2 diabetes and related cardiovascular complications.", "results_summary": "The study found that EGCG exhibits insulin-mimetic effects, improving endothelial dysfunction and metabolic insulin resistance in skeletal muscle and liver, making it a promising therapeutic for conditions like obesity, metabolic syndrome, and type 2 diabetes.", "population_specificity": "Insulin-resistant and diabetic populations (based on rationale for future trials).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:27.067522+00:00"}
{"study_id": 56001, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to review the potential anti-cancer and chemopreventive activities of Epigallocatechin Gallate (EGCG) and its role in inhibiting the mTOR pathway.", "results_summary": "The abstract suggests that EGCG, among other natural compounds, inhibits the mTOR pathway, which is commonly activated in human cancers, indicating potential anti-cancer and chemopreventive effects. Some of these compounds, including EGCG, are in clinical trials.", "population_specificity": "Not specified (general preclinical and clinical research context)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:27.899174+00:00"}
{"study_id": 56004, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the potential of epigallocatechin gallate as an effective MMP inhibitor to reduce the progression of dentine erosion.", "results_summary": "The study identified epigallocatechin gallate as an effective MMP inhibitor, suggesting its potential to reduce dentine erosion progression, alongside fluoride and chlorhexidine. However, further development and validation of alternative approaches with greater protective capacity are needed.", "population_specificity": "Not specified (implied focus on individuals with dental erosion or advanced erosive lesions).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:29.112712+00:00"}
{"study_id": 56007, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to review the pleiotropic beneficial effects of epigallocatechin gallate on cardiovascular diseases associated with endothelial dysfunction and identify its potential protective vascular effects.", "results_summary": "The study found that epigallocatechin gallate improves endothelium-dependent vasodilation by increasing nitric oxide bioactivity, prevents endothelial cell apoptosis, and modulates inflammatory signaling pathways, suggesting its potential in preventing cardiovascular diseases.", "population_specificity": "General population (not specified)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:33.007891+00:00"}
{"study_id": 56005, "supplement_id": 1110, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether high-dose EGCG supplementation impairs COMT activity in vivo and its potential effects on COMT-mediated metabolism.", "results_summary": "The study found that 750 mg EGCG supplementation did not impair COMT activity; instead, it increased COMT activity by 24%. EGCG plasma levels rose post-intervention but were unaffected by COMT polymorphisms.", "population_specificity": "24 healthy human volunteers (14 women, 10 men).", "effective_dosage": "750 mg EGCG (single dose).", "study_duration": "Single intervention with measurements taken before and 2 hours after.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:33.286282+00:00"}
{"study_id": 56008, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to review the role of Epigallocatechin Gallate as a natural modulator of NAG-1 in cancer cells.", "results_summary": "Epigallocatechin Gallate was found to elicit NAG-1 overexpression in various cancer cells, suggesting its potential role in cancer prevention and treatment through transcriptional mechanisms. The study highlights its inclusion among other phytochemicals with similar effects.", "population_specificity": "Human colon cancer or hepatocarcinoma cells (in vitro).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:34.271263+00:00"}
{"study_id": 56009, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were examining the limitations of traditional antioxidant therapies and proposing autophagy-lysosomal activities as an alternative approach for addressing oxidative damage in neurodegenerative diseases.", "results_summary": "The abstract does not specifically discuss Epigallocatechin Gallate but highlights the limitations of radical scavenging antioxidants and suggests autophagy-lysosomal activities as a potential alternative for mitigating oxidative damage in neurodegeneration.", "population_specificity": "Not specified (abstract discusses general oxidative stress and neurodegeneration).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:34.532408+00:00"}
{"study_id": 56006, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the acute effects of epigallocatechin gallate (EGCG), alone or combined with caffeine, on cognitive function and mood in humans.", "results_summary": "The study found moderate effect sizes favoring combined caffeine and L-theanine (with EGCG) for improving alertness and attentional switching accuracy within the first 2 hours postdose, with lesser effects on unisensory and multisensory attention. Caffeine dose had a greater influence on effect size than L-theanine dose, particularly in the first hour.", "population_specificity": "Human participants in randomized placebo-controlled trials (specific demographics not detailed).", "effective_dosage": "Not specified for EGCG alone (study focused on combinations with caffeine and L-theanine).", "study_duration": "Acute effects assessed within the first 2 hours postdose.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:35.822588+00:00"}
{"study_id": 56010, "supplement_id": 1110, "safety_score": "85", "efficacy_score": 30, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether Polyphenon E (containing epigallocatechin gallate) could promote clearance of persistent high-risk HPV and related CIN1 in women with these conditions.", "results_summary": "Polyphenon E was safe and well-tolerated but showed no significant difference in HPV or CIN1 clearance compared to placebo. Progression of disease was slightly more common in the Polyphenon E group.", "population_specificity": "Women with persistent HPV infection and low-grade cervical intraepithelial neoplasia (CIN1).", "effective_dosage": "800 mg epigallocatechin gallate once daily.", "study_duration": "4 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:36.022430+00:00"}
{"study_id": 56011, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the potential of Epigallocatechin Gallate (EGCG) as a compound targeting immunoinflammatory and oxidative/nitrosative stress pathways in depression.", "results_summary": "The study suggests EGCG, as an antioxidant, may help mitigate oxidative and nitrosative stress pathways implicated in depression, potentially improving symptom patterns and neuroprogression. However, specific efficacy data for EGCG in depression were not detailed.", "population_specificity": "Not specified (general review of depression-related pathways).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:36.294725+00:00"}
{"study_id": 56012, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether Epigallocatechin Gallate (EGCG) could rescue cognitive deficits in Down syndrome (DS) by inhibiting DYRK1A kinase activity.", "results_summary": "EGCG improved cognitive deficits in both mouse models and a pilot human study, enhancing memory recognition, working memory, and quality of life. It reduced DYRK1A activity in the hippocampus and altered plasma homocysteine levels, which correlated with Dyrk1A expression.", "population_specificity": "Down syndrome (DS) individuals and mouse models (Ts65Dn and transgenic mice overexpressing Dyrk1A).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:38.185254+00:00"}
{"study_id": 56013, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the anti-diabetic effects of dietary flavonoids, including Epigallocatechin Gallate, focusing on their mechanisms of action in glucose and lipid homeostasis.", "results_summary": "The study found that flavonoids, including Epigallocatechin Gallate, may improve glucose and lipid metabolism by enhancing insulin secretion, reducing apoptosis in pancreatic \u03b2-cells, regulating glucose metabolism in hepatocytes, and increasing glucose uptake in muscle and fat tissues. The effects were noted to be comparable to clinically-used anti-diabetic drugs at physiological concentrations.", "population_specificity": "Not specified (general review of in vitro, animal, and epidemiological studies)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:41.561632+00:00"}
{"study_id": 56016, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of Epigallocatechin Gallate (EGCG) as part of the epigenetic diet in modulating age-related diseases through epigenetic mechanisms.", "results_summary": "The study suggests that EGCG, along with other bioactive compounds, may slow aging and age-related diseases by influencing histone modification, DNA methylation, and microRNA expression. However, specific outcomes for EGCG alone are not detailed in the abstract.", "population_specificity": "Pre-clinical and clinical studies (general population, not specified).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:42.635362+00:00"}
{"study_id": 56014, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether a combination of bioactive food ingredients, including Epigallocatechin Gallate, could enhance satiety and thermogenesis in overweight adults.", "results_summary": "The study found that the supplemented group experienced a significantly greater increase in satiety compared to the placebo group, suggesting the combination may be effective in promoting satiety and thermogenesis. All measured parameters increased significantly post-meal, but the supplemented group showed superior satiety effects.", "population_specificity": "Overweight adults (BMI: 25-35; 37 participants, aged 40.8 \u00b1 11.5 to 46.4 \u00b1 6.4).", "effective_dosage": "Not specified", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:43.362871+00:00"}
{"study_id": 56015, "supplement_id": 1110, "safety_score": "90", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to assess the effectiveness and safety of an EGCG-enriched tea drink (DBGT) as a maintenance treatment to prevent recurrence in women with advanced-stage ovarian cancer after standard therapy.", "results_summary": "The study found that DBGT supplementation was not effective in preventing recurrence, with only 5 out of 16 women remaining recurrence-free at 18 months. No severe toxicity was reported, and adherence to the intervention was high.", "population_specificity": "Women with FIGO stage III-IV serous or endometrioid ovarian cancer who achieved complete response after debulking surgery and platinum/taxane chemotherapy.", "effective_dosage": "500 mL daily", "study_duration": "Until recurrence or up to 18 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:43.561880+00:00"}
{"study_id": 56017, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to examine the chemopreventive potential of flavonoids, particularly epigallocatechin gallate (EGCG), in human oral carcinogenesis.", "results_summary": "The study reported a high level of evidence for EGCG as a promising chemopreventive agent in human oral cancer, though clinical trial and epidemiological data were limited compared to preclinical studies. EGCG, abundant in green tea, showed significant potential in reducing cancer risk.", "population_specificity": "Human oral carcinogenesis (specific population details not provided).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:44.105479+00:00"}
{"study_id": 56019, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review preclinical research strategies, including the potential of Epigallocatechin Gallate (EGCG) to counteract cognitive and adaptive deficits in Down syndrome mouse models.", "results_summary": "The abstract suggests EGCG, as part of DYRK1A modulation, shows promise in rescuing learning/memory deficits in DS mouse models, though clinical applicability remains under investigation.", "population_specificity": "Mouse models of Down syndrome (trisomy 21).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:44.376916+00:00"}
{"study_id": 56021, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention Epigallocatechin Gallate or its study.", "results_summary": "The abstract does not discuss Epigallocatechin Gallate or its effects.", "population_specificity": "Not specified (abstract focuses on gastric cancer and DNA methylation).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:48.714581+00:00"}
{"study_id": 56020, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to investigate the growth inhibitory effects of EGCG combined with quercetin on different types of breast cancer cells.", "results_summary": "The study found that quercetin combined with 5GG (an analogue of EGCG) was more effective in inhibiting MDA-MB-231 cell growth than quercetin combined with EGCG. EGCG's effects were less pronounced compared to 5GG in this context.", "population_specificity": "Estrogen receptor (ER)/human epidermal growth factor 2 (Her2)-negative (MDA-MB-231), ER-positive/Her2-negative (BT483), and ER-negative/Her2-positive (AU565) breast cancer cells.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:50.871990+00:00"}
{"study_id": 56022, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of combining Epigallocatechin Gallate (EGCG) with sulforaphane (SFN) as a demethylating agent to re-express estrogen receptor in hormone-negative breast cancer.", "results_summary": "The study found that combining EGCG with SFN was an effective approach for re-expressing estrogen receptor in hormone-negative breast cancer, suggesting potential therapeutic benefits in epigenetic modulation for cancer treatment.", "population_specificity": "Hormone-negative breast cancer (specific human population not detailed in abstract).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:51.428372+00:00"}
{"study_id": 56024, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to summarize the potential chemopreventive effects of Epigallocatechin Gallate and other natural bioactive compounds against gastroenterological cancers.", "results_summary": "The study suggests that Epigallocatechin Gallate, along with other phytochemicals, may help prevent, suppress, or delay gastroenterological cancers by regulating specific molecules with antioxidant, anti-inflammatory, and anti-carcinogenic activities.", "population_specificity": "General focus on individuals at risk for gastroenterological cancers (esophageal, gastric, and colon cancers).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:51.772109+00:00"}
{"study_id": 56023, "supplement_id": 1110, "safety_score": "70", "efficacy_score": 80, "quality_score": 65, "study_goal": "The researchers aimed to determine whether green tea extracts containing Epigallocatechin Gallate (EGCG) could modulate circulating Tregs and control lymphocytosis in early-stage chronic lymphocytic leukemia (CLL) patients.", "results_summary": "The study found that 80% of evaluable patients showed reduced lymphocytosis and Tregs, while one patient stabilized and one worsened. IL-10 and TGF-beta levels declined in both patients and controls during green tea intake.", "population_specificity": "12 patients with stage 0 CLL and 12 healthy subjects.", "effective_dosage": "Not specified.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:52.020310+00:00"}
{"study_id": 56026, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of EGCG and its metabolites on bioavailability, intracellular metabolism, and antiproliferative activity in colon cancer cells.", "results_summary": "EGCG and 3,4-DHPAA showed an additive antiproliferative effect in HCT-116 colon cancer cells, with decreased methylation of 3,4-DHPAA. Consumption of green and black tea increased urinary and serum phenolic acids.", "population_specificity": "Men (specific details not provided beyond gender).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:53.055634+00:00"}
{"study_id": 56025, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the effectiveness of epigallocatechin gallate in fibroid regression and symptomatic improvement.", "results_summary": "The study found that epigallocatechin gallate was effective for fibroid regression and symptomatic improvement, though it is still in clinical trials.", "population_specificity": "Reproductive-age women with uterine leiomyomas (fibroids).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:54.426060+00:00"}
{"study_id": 56027, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether a combination of bioactive food ingredients, including Epigallocatechin Gallate, could improve metabolic changes in overweight subjects following a therapeutic lifestyle change diet.", "results_summary": "The study found that the supplement combination significantly improved insulin resistance, leptin/adiponectin ratio, respiratory quotient, LDL-cholesterol, and resting energy expenditure, with greater changes in the supplemented group compared to placebo, though not all differences were statistically significant between groups.", "population_specificity": "86 overweight subjects (BMI ~30 kg/m\u00b2, age ~40-44 years).", "effective_dosage": "Not specified", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:57.502509+00:00"}
{"study_id": 56029, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review the applications of EGCG and its analogs, derivatives, and prodrugs in cancer prevention and treatment, focusing on patented advancements.", "results_summary": "The study found that EGCG targets multiple cancer cell survival pathways but has poor oral bioavailability, leading to the development of derivatives and prodrugs to enhance stability and efficacy. Patented modifications aim to improve its anticancer potential for chemoprevention and therapy.", "population_specificity": "Human cancer cells (in vitro or in vivo context, not specified further).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:59.893006+00:00"}
{"study_id": 56028, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the therapeutic effects of intravesical EGCG irrigation on interstitial cystitis (IC) symptoms and its impact on purinergic receptor expression and ATP release in bladder urothelial cells.", "results_summary": "EGCG treatment led to symptom remission in IC patients, reduced purinergic receptor expression, and inhibited ATP release in stretched urothelial cells. It also demonstrated antioxidative and anti-inflammatory effects by suppressing iNOS and phosphorylated NF-\u03baB.", "population_specificity": "Eight IC patients and six asymptomatic control subjects matched by age, race, and sex.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:46:59.909166+00:00"}
{"study_id": 56032, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the protective effects of epigallocatechin gallate (EGCG) as an MMP inhibitor against dentin erosion and erosion plus abrasion.", "results_summary": "EGCG demonstrated a pronounced protective effect against dentin erosion and erosion plus abrasion, with long-lasting efficacy observed for up to 10 days under severe erosive challenges. The protection was more effective when delivered in gel form compared to other formulations.", "population_specificity": "Not specified (in vitro and in situ studies, likely involving human dentin samples).", "effective_dosage": "Not specified", "study_duration": "Up to 10 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:01.348900+00:00"}
{"study_id": 56030, "supplement_id": 1110, "safety_score": "85", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to assess the safety, tolerability, and disposition of a single oral dose of EGCG in cirrhotic patients with HCV.", "results_summary": "The study found that a single 400-mg dose of EGCG was safe and well-tolerated, with no significant differences in disposition between cirrhotic and noncirrhotic patients. However, the study did not evaluate long-term safety or therapeutic efficacy.", "population_specificity": "Eleven patients with hepatitis C (4 Child-Pugh class A cirrhosis, 4 class B cirrhosis, 3 noncirrhotic).", "effective_dosage": "400 mg (single dose, 94% pure EGCG).", "study_duration": "Single dose, monitored for 10 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:01.554498+00:00"}
{"study_id": 56033, "supplement_id": 1110, "safety_score": "80", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the chemosensitizing potential of Epigallocatechin Gallate (EGCG) and its ability to regulate survival pathways without inducing toxicity.", "results_summary": "The study suggests EGCG can modulate key regulators of chemoresistance and has potential as a chemosensitizer, but clinical efficacy requires further investigation. Current clinical trials indicate promising but inconclusive results.", "population_specificity": "Not specified (general review of clinical trials and research).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:03.268639+00:00"}
{"study_id": 56034, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the molecular targets and predictive biomarkers of Epigallocatechin Gallate in the context of personalized cancer chemoprevention.", "results_summary": "The abstract highlights progress in identifying molecular targets of Epigallocatechin Gallate, suggesting optimism for its role in cancer prevention, but does not provide specific efficacy results.", "population_specificity": "Not specified", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:04.865599+00:00"}
{"study_id": 56036, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the role of Epigallocatechin Gallate as an NF-\u03baB inhibitor in ocular surface disorders.", "results_summary": "The study suggests Epigallocatechin Gallate may inhibit NF-\u03baB, potentially reducing corneal angiogenesis in alkali injury, indicating therapeutic potential for ocular conditions.", "population_specificity": "Ocular surface disorders (e.g., chemical injury, infections, dry eye).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:07.238606+00:00"}
{"study_id": 56035, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the effects of Epigallocatechin Gallate on osteoarthritis, focusing on its molecular antiosteoarthritic mechanisms.", "results_summary": "The abstract suggests that Epigallocatechin Gallate, among other polyphenols, may help prevent osteoarthritis-related musculoskeletal inflammation, but specific results or mechanisms are not detailed.", "population_specificity": "Not specified (general osteoarthritis-related musculoskeletal inflammation context).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:08.484666+00:00"}
{"study_id": 56038, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to explore whether Epigallocatechin gallate, by modulating DYRK1A functioning, could be a useful therapeutic approach for Down syndrome patients.", "results_summary": "The study preliminarily suggests that Epigallocatechin gallate may be beneficial in normalizing the expression or function of candidate molecules, offering a potential therapeutic alternative for Down syndrome. However, the abstract does not provide detailed results or statistical significance.", "population_specificity": "Down syndrome patients (demented and young nondemented).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:10.497412+00:00"}
{"study_id": 56031, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the changes in plasma and urine levels of catechins, including Epigallocatechin Gallate (EGCG), after single and repeated doses of green tea.", "results_summary": "The study found elevated plasma levels of EGCG and other catechins post-ingestion, with EGCG showing significant increases after both acute and chronic consumption. Chronic intake led to sustained ECG levels but minimal fasting EGC, suggesting differential absorption and metabolism among catechins.", "population_specificity": "Sixteen healthy volunteers.", "effective_dosage": "Single dose of 200 ml of 1.5% (w/v) green tea; chronic dose of 150 ml of 1% (w/v) green tea twice daily.", "study_duration": "Acute (single dose) and chronic (1 week).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:11.142781+00:00"}
{"study_id": 56039, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of epigallocatechin gallate as an antioxidant therapy to mitigate oxidative stress and damage caused by sulfur mustard poisoning.", "results_summary": "The study suggests that epigallocatechin gallate, along with other antioxidants, shows promise in ameliorating oxidative stress and tissue damage induced by sulfur mustard, though specific efficacy data are not detailed in the abstract.", "population_specificity": "Not specified (general oxidative stress context, likely preclinical or animal models based on abstract).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:12.000447+00:00"}
{"study_id": 56037, "supplement_id": 1110, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the clinical efficacy and safety of Polyphenon E (standardized to EGCG) in patients with early-stage chronic lymphocytic leukemia (CLL).", "results_summary": "The study found that oral EGCG was well tolerated, with 69% of patients showing a biologic response (reduced lymphocyte counts or lymphadenopathy). Clinical activity included sustained ALC reductions in 31% of patients and significant lymphadenopathy improvement in 69% of those with palpable adenopathy.", "population_specificity": "Previously untreated patients with asymptomatic, Rai stage 0 to II CLL and an ALC \u2265 10 \u00d7 10\u2079/L.", "effective_dosage": "2000 mg twice daily.", "study_duration": "Up to 6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:12.408139+00:00"}
{"study_id": 56040, "supplement_id": 1110, "safety_score": "85", "efficacy_score": 40, "quality_score": 80, "study_goal": "The researchers aimed to assess the effects of oral EGCG on cognitive performance, mood, and cerebral blood flow in healthy adults.", "results_summary": "A single 135 mg dose of EGCG reduced frontal cortex blood flow but did not affect cognitive performance or mood. No significant changes were observed in deoxygenated hemoglobin or heart rate differences between treatments.", "population_specificity": "27 healthy human adults", "effective_dosage": "135 mg and 270 mg, single dose", "study_duration": "Single administration with 45-min absorption and 42-min task period", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:12.998168+00:00"}
{"study_id": 56042, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether epigallocatechin gallate (EGCG) modulates brain activity and self-reported mood in humans.", "results_summary": "EGCG administration significantly increased alpha, beta, and theta EEG activity, particularly in frontal regions, and improved self-rated calmness while reducing stress compared to placebo. The findings suggest EGCG promotes a relaxed yet attentive state.", "population_specificity": "Not specified (participants in a double-blind, placebo-controlled crossover study).", "effective_dosage": "300 mg (single dose).", "study_duration": "Acute effects measured 120 minutes post-administration.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:17.043143+00:00"}
{"study_id": 56041, "supplement_id": 1110, "safety_score": "85", "efficacy_score": 70, "quality_score": 90, "study_goal": "The researchers aimed to investigate the effects of epigallocatechin gallate (EGCG) from green tea extract on circulating hormone levels and metabolic markers in postmenopausal women.", "results_summary": "EGCG supplementation did not consistently alter estrogen or testosterone levels but significantly reduced LDL-cholesterol and showed suggestive beneficial effects on glucose and insulin levels.", "population_specificity": "Postmenopausal women (n = 103)", "effective_dosage": "400-mg or 800-mg EGCG as polyphenon E (PPE) capsules per day", "study_duration": "2 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:17.045550+00:00"}
{"study_id": 56045, "supplement_id": 1110, "safety_score": "80", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine whether green tea extract containing 300 mg EGCG daily could prevent the recurrence of colon adenomas in patients who had undergone polypectomy.", "results_summary": "The study design suggests potential efficacy, but final results on adenoma recurrence rates are pending as the trial is ongoing. The abstract highlights the favorable safety profile and cancer-preventive potential of EGCG.", "population_specificity": "Patients who had undergone polypectomy for colonic polyps.", "effective_dosage": "150 mg EGCG twice daily (total 300 mg/day).", "study_duration": "Three years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:20.467908+00:00"}
{"study_id": 56043, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to review and summarize current literature on the mechanisms by which epigallocatechin gallate (GTC) may prevent prostate cancer, based on laboratory, in vitro, in vivo, and clinical studies.", "results_summary": "The study found that epigallocatechin gallate can induce apoptosis, suppress progression, and inhibit invasion and metastasis of prostate cancer through multiple molecular pathways. Epidemiological and clinical evidence suggests green tea consumption has protective effects against prostate cancer.", "population_specificity": "Primarily focused on prostate cancer, with references to laboratory, in vitro, in vivo, and clinical trial data.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:20.890541+00:00"}
{"study_id": 56044, "supplement_id": 1110, "safety_score": "80", "efficacy_score": 40, "quality_score": 85, "study_goal": "The researchers aimed to determine the bioavailability of green tea polyphenols in prostate tissue and measure their effects on systemic and tissue biomarkers of prostate cancer carcinogenesis.", "results_summary": "The study found low to undetectable levels of green tea polyphenols in prostate tissue, with favorable but statistically insignificant changes in serum biomarkers and no significant differences in tissue biomarkers between treatment arms. A greater proportion of subjects on polyphenon E showed a decrease in Gleason score, but this was not statistically significant.", "population_specificity": "Men with prostate cancer scheduled to undergo radical prostatectomy.", "effective_dosage": "800 mg epigallocatechin gallate daily.", "study_duration": "3 to 6 weeks before surgery.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:21.315195+00:00"}
{"study_id": 56047, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to explore the potential of Epigallocatechin Gallate (EGCG) as an anti-angiogenic agent for cancer treatment, focusing on its role in inhibiting pathways critical for tumor growth.", "results_summary": "The abstract highlights EGCG as a prominent phytochemical with anti-angiogenic properties, affecting multiple pathways involved in tumor growth, though specific efficacy data or clinical outcomes are not detailed.", "population_specificity": "Not specified (general focus on cancer-related angiogenesis).", "effective_dosage": "Not provided.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:21.394183+00:00"}
{"study_id": 56048, "supplement_id": 1110, "safety_score": "85", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to examine the effect of a decaffeinated green tea extract (GTE) providing 856 mg of EGCG daily on insulin resistance and metabolic parameters in obese individuals with type 2 diabetes.", "results_summary": "The study found no statistically significant differences between the GTE and placebo groups in any measured variable. However, within-group comparisons showed significant reductions in HbA1C, waist circumference, HOMA-IR index, and insulin levels in the GTE group, along with increased ghrelin levels.", "population_specificity": "Obese individuals (BMI > 25 kg/m\u00b2) aged 20-65 with type 2 diabetes for over one year.", "effective_dosage": "1,500 mg of decaffeinated GTE daily (providing 856 mg EGCG).", "study_duration": "16 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:22.901402+00:00"}
{"study_id": 56049, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to understand the preventive and therapeutic effects of Epigallocatechin Gallate (EGCG) in various stages of carcinogenesis.", "results_summary": "The study suggests that EGCG, among other flavonoids, shows beneficial effects in modulating cellular and molecular mechanisms related to carcinogenesis, based on in vitro and animal model data. Epidemiological studies support its potential role in cancer prevention.", "population_specificity": "Not specified (in vitro, animal models, and general epidemiological data).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:25.121797+00:00"}
{"study_id": 56050, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to evaluate whether epigallocatechin gallate (EGCG) could protect against A\u03b2-induced oxidative stress in Alzheimer's disease.", "results_summary": "The abstract suggests that EGCG, among other antioxidants, may help combat oxidative stress linked to Alzheimer's disease by scavenging free radicals and inducing protective genes. However, specific results for EGCG alone are not detailed.", "population_specificity": "Not specified (general focus on Alzheimer's disease pathology).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:26.488365+00:00"}
{"study_id": 56018, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to explore the effects of polyphenols, including Epigallocatechin Gallate, on brain ageing and neurodegeneration, with a focus on their potential mechanisms of action and implications for Alzheimer's disease treatment.", "results_summary": "The abstract suggests that Epigallocatechin Gallate has antioxidant, anti-amyloidogenic, and cell-signaling modulation properties, which may help reduce hallmarks of Alzheimer's disease, though evidence for its efficacy remains limited.", "population_specificity": "Not specified (general focus on neurodegeneration and ageing).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:27.036404+00:00"}
{"study_id": 56051, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to explore how Epigallocatechin Gallate (EGCG) modulates inflammatory pathways, particularly NF-\u03baB, to potentially reduce cancer-related symptoms.", "results_summary": "The abstract suggests that EGCG, among other nutritional agents, may modulate inflammatory pathways and reduce cancer-related symptoms, but specific results for EGCG alone are not detailed.", "population_specificity": "Cancer patients with symptoms like cachexia, anorexia, fatigue, and neuropathic pain.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:28.482631+00:00"}
{"study_id": 56052, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether epigallocatechin gallate could overcome chemotherapy resistance in B-lineage acute lymphoblastic leukemia (ALL) by inhibiting HSPA5.", "results_summary": "Epigallocatechin gallate effectively inhibited HSPA5's anti-apoptotic function, overcoming vincristine resistance in B-lineage ALL cells. The study also noted apoptosis in chemotherapy-resistant cells when exposed to a targeted anti-HSPA5 peptide.", "population_specificity": "Relapsed B-lineage acute lymphoblastic leukemia (ALL) cells.", "effective_dosage": "Not specified", "study_duration": "48 hours (for apoptosis observation)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:29.495466+00:00"}
{"study_id": 56054, "supplement_id": 1110, "safety_score": "80", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate Epigallocatechin Gallate as a potential maintenance therapy for B-chronic lymphocytic leukemia (CLL) due to its ability to inhibit survival signals in the tumor microenvironment.", "results_summary": "The abstract suggests that Epigallocatechin Gallate is well tolerated and inhibits survival signals necessary for tumor development, making it a candidate for CLL maintenance therapy. However, specific efficacy data or clinical outcomes are not detailed.", "population_specificity": "Patients with B-chronic lymphocytic leukemia (CLL).", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:29.694167+00:00"}
{"study_id": 56053, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the impact of COMT genotype on the absorption and metabolism of green tea catechins, particularly Epigallocatechin Gallate (EGCG), in humans.", "results_summary": "The study found that COMT genotype did not significantly influence EGCG absorption and elimination. Bimodal plasma concentration curves were observed for non-gallated catechins (EGC and EC), while gallated catechins (EGCG and ECG) showed single-peaked curves.", "population_specificity": "20 participants (10 of each homozygous COMT genotype).", "effective_dosage": "1.1 g of Sunphenon decaffeinated green tea extract (836 mg green tea catechins).", "study_duration": "Single dose with plasma concentration profiles measured over time.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:31.127215+00:00"}
{"study_id": 56055, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine the molecular mechanism by which EGCG suppresses human pancreatic cancer cell proliferation.", "results_summary": "EGCG significantly suppressed the growth of pancreatic cancer cells (AsPC-1 and BxPC-3) in a dose-dependent manner, primarily by blocking FAK and IGF-1R activation without inducing apoptosis. The MEK1/2 inhibitor U0126 enhanced EGCG's growth-suppressive effects.", "population_specificity": "Human pancreatic cancer cell lines (AsPC-1 and BxPC-3).", "effective_dosage": "100 \u03bcM (single dose mentioned).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:31.603628+00:00"}
{"study_id": 56057, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether EGCG affects CD11b expression on B cells and its impact on B-cell migration and adhesion, similar to its effects on cytotoxic T cells.", "results_summary": "EGCG significantly suppressed CD11b expression on B cells, reducing their adhesive and migratory abilities. This suppression was mediated by EGCG binding to CD11b, suggesting potential for treating allergic and autoimmune diseases.", "population_specificity": "Isolated peripheral blood CD19(+) B cells", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:33.031903+00:00"}
{"study_id": 56058, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to review the role of mTOR inhibitors, including natural products like Epigallocatechin Gallate (EGCG), as potential anticancer agents.", "results_summary": "The study found that EGCG, along with other natural products, inhibits mTOR signaling, which is implicated in cancer progression. However, specific efficacy data for EGCG were not detailed in the abstract.", "population_specificity": "Not specified (general review of mTOR inhibitors in preclinical and clinical contexts).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:34.595665+00:00"}
{"study_id": 56060, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of Epigallocatechin Gallate (EGCG) as an inhibitor of Abeta aggregation and its effectiveness in reducing amyloid levels in transgenic mouse models of Alzheimer's disease.", "results_summary": "The study found that EGCG, along with other polyphenolic compounds, attenuates Abeta aggregation through distinct mechanisms and reduces amyloid levels in transgenic mouse models of AD, suggesting potential therapeutic benefits.", "population_specificity": "Transgenic mouse models of Alzheimer's disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:36.352717+00:00"}
{"study_id": 56059, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the chemopreventive potential and clinical applications of Epigallocatechin Gallate, focusing on its mechanisms of inducing apoptosis and arresting cell growth.", "results_summary": "The study suggests that Epigallocatechin Gallate shows promise as a chemopreventive agent, inducing apoptosis and inhibiting cell growth through pleiotropic mechanisms, with potential benefits in monotherapy or combined with chemotherapeutic drugs. However, clinical trials are limited, though preliminary results are encouraging.", "population_specificity": "Not specified (cellular and animal studies mentioned, human applicability inferred but not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:36.883855+00:00"}
{"study_id": 187852, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of green tea catechins (GTC), particularly epigallocatechin gallate (EGCG), on resting metabolic rate (RMR), energy expenditure (EE), and respiratory quotient (RQ).", "results_summary": "The study found that GTC intake, with EGCG doses between 100-800 mg, was associated with modulations in fat metabolism and weight loss, though specific effect sizes and consistency across studies were not detailed in the abstract.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "100-800 mg of EGCG.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:38.436699+00:00"}
{"study_id": 187853, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the impact of tea consumption, particularly its active ingredient epigallocatechin gallate, on endothelial function and cardiovascular disease risk markers in individuals at risk of CVD or with CAD.", "results_summary": "The study found that regular tea consumption, including epigallocatechin gallate, improved endothelial function by enhancing nitric oxide bioavailability, reducing oxidative stress and inflammation markers (e.g., oxidized LDL and C-reactive protein), and potentially lowering CVD risk. The evidence suggests epigallocatechin gallate could be developed as a nutraceutical for vascular health benefits.", "population_specificity": "Individuals at risk of cardiovascular disease or patients with coronary artery disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:39.786275+00:00"}
{"study_id": 187856, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of 1 and 7 days of green tea extract (GTE) ingestion on whole-body fat oxidation during moderate-intensity exercise.", "results_summary": "One day of GTE ingestion had no effect on lipolysis or fat oxidation. Seven days of GTE increased lipolysis (plasma FA and glycerol) but did not significantly change fat oxidation.", "population_specificity": "31 men", "effective_dosage": "Not specified", "study_duration": "1 or 7 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:40.680113+00:00"}
{"study_id": 187855, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine the effects of short-term supplementation with epigallocatechin gallate (E) combined with resveratrol (R) and soy isoflavones (S) on energy expenditure and substrate metabolism in overweight individuals.", "results_summary": "Short-term supplementation with E+R increased resting and postprandial energy expenditure, and improved metabolic flexibility in men but not women. Adding soy isoflavones partially reversed these effects, possibly due to increased lipolysis.", "population_specificity": "Overweight adults (9 women, 9 men; age 35\u00b12.5 years; BMI 28.9\u00b10.4 kg/m\u00b2).", "effective_dosage": "282 mg/day epigallocatechin gallate + 200 mg/day resveratrol, supplemented twice daily.", "study_duration": "3 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:42.162876+00:00"}
{"study_id": 187857, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of a supplement containing 105 mg of EGCG in improving compliance to a low-caloric diet and its effects on body composition, appetite, mood, and binge eating in overweight adults.", "results_summary": "The supplement improved dietary compliance and mood at week 4, but these effects were not sustained by week 8. No significant differences were observed in body mass, body composition, hunger, or binge eating after eight weeks.", "population_specificity": "Healthy, overweight adults (BMI > 25) including 15 men and 35 women.", "effective_dosage": "105 mg of EGCG daily.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:43.993012+00:00"}
{"study_id": 187858, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers examined whether combining epigallocatechin gallate (EGCG) with other flavonoids and antioxidants could reduce oxidative stress markers post-exercise.", "results_summary": "The study found that the combination including EGCG (QFO group) reduced the immediate post-exercise increase in F(2)-isoprostanes, indicating reduced oxidative stress, independent of changes in plasma antioxidant capacity.", "population_specificity": "39 athletes", "effective_dosage": "30 mg EGCG daily (as part of QFO formulation)", "study_duration": "2 weeks before and during 3 days of cycling", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:44.692828+00:00"}
{"study_id": 12960, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the relationships between FGF23, ESA treatment, ESA resistance, and endogenous EPO in hemodialysis patients.", "results_summary": "Higher ESA dose was associated with higher FGF23 levels, and higher C-terminal FGF23 was linked to higher ESA resistance index, lower hemoglobin, and higher endogenous EPO, while intact FGF23 showed no such associations.", "population_specificity": "654 maintenance hemodialysis patients (458 treated with ESAs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:44.756449+00:00"}
{"study_id": 12961, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the long-term effects of erythropoiesis-stimulating agents (ESAs) on survival and health-related quality of life (HRQoL) in patients with lower-risk myelodysplastic syndromes.", "results_summary": "ESA treatment significantly improved overall survival (median 44.9 months vs. 34.8 months in the unexposed group) and avoiding red blood cell transfusions (RBCT) was associated with better HRQoL. The study found a 10.1-month absolute survival benefit with ESA treatment.", "population_specificity": "Patients older than 18 years with lower-risk myelodysplastic syndromes (IPSS low or intermediate-1) from 16 European countries and Israel, with hemoglobin <100 g/L.", "effective_dosage": "Not specified (followed local guidelines).", "study_duration": "Median follow-up time was 3.9 years (IQR 1.6-6.5).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:49.936249+00:00"}
{"study_id": 12962, "supplement_id": 1111, "safety_score": "80", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to assess the impact of ESA use on tumor recurrence, cancer-specific survival, and overall survival in patients with ESRD and early-stage urothelial carcinoma.", "results_summary": "ESA use did not significantly affect bladder recurrence-free survival, CSS, or OS in NMIBC patients, nor did it negatively impact these outcomes in localized UTUC patients. However, UTUC patients treated with ESA showed a significantly increased risk of contralateral recurrence.", "population_specificity": "Patients with end-stage renal disease (ESRD) and early-stage urothelial carcinoma (non-muscle-invasive bladder cancer or localized upper tract urothelial carcinoma).", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:50.198104+00:00"}
{"study_id": 12964, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 68, "study_goal": "The researchers aimed to examine the relationship between thrombo-inflammatory and oxidative stress-related biomarkers and ESA hyporesponsiveness in chronic hemodialysis patients.", "results_summary": "The study found that low BMI and high levels of plasminogen activator inhibitor-1 and L-FABP were significant predictors of ESA resistance, with BMI \u2264 25.46 kg/m\u00b2 and L-FABP > 5355.24 ng/mL indicating higher odds of resistance.", "population_specificity": "96 patients undergoing chronic hemodialysis, 58 of whom received ESAs.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:51.021157+00:00"}
{"study_id": 12963, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine the incidence and clinical characteristics of hyporesponsiveness to Erythropoiesis-Stimulating Agents (ESAs) in patients with chronic kidney disease, comparing different definitions of hyporesponsiveness.", "results_summary": "The study found varying incidence rates of ESA hyporesponsiveness depending on the definition used (5.2% to 47.9% of patients). Hyporesponsive patients required higher ESA doses but achieved similar hemoglobin levels as responsive patients.", "population_specificity": "Adults with stage 5 chronic kidney disease receiving renal replacement therapy and ESA treatment.", "effective_dosage": "Median starting dose was 733.3 IU/week (interquartile range: 400.0, 1200.0).", "study_duration": "Median follow-up duration was 2.2 years (interquartile range: 1.0, 4.2).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:51.454043+00:00"}
{"study_id": 12967, "supplement_id": 1111, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects and risks of erythropoiesis-stimulating agents (ESAs) in reducing anemia and improving outcomes in lung cancer patients through a meta-analysis of randomized controlled trials.", "results_summary": "ESAs did not increase mortality in lung cancer patients and may reduce the risk of death, while also decreasing blood transfusion requirements. However, ESAs were associated with an increased incidence of thrombotic vascular events.", "population_specificity": "Lung cancer patients (including small cell and non-small cell subtypes).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:53.002560+00:00"}
{"study_id": 12966, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 30, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the benefits and harms of Erythropoiesis-Stimulating Agents (ESAs) for preventing acute kidney injury (AKI) in at-risk populations.", "results_summary": "ESAs showed little to no difference in reducing the risk of AKI, death, or dialysis initiation compared to control interventions. No significant differences were observed in adverse events like thrombosis, myocardial infarction, stroke, or hypertension.", "population_specificity": "Hospitalized adults at risk of AKI, including those undergoing cardiac surgeries, children, neonates, and other adults.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:53.069909+00:00"}
{"study_id": 12968, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 26, "quality_score": 65, "study_goal": "The researchers aimed to evaluate treatment patterns, clinical outcomes, and healthcare resource utilization among patients with lower-risk myelodysplastic syndromes (LR-MDS) treated with erythropoiesis-stimulating agents (ESAs) in the United States.", "results_summary": "The study found poor clinical outcomes with ESA therapy, including low hematologic improvement (26%) and high primary ESA failure (65%). The treatment also imposed a significant burden on the health system and patients.", "population_specificity": "Patients with lower-risk myelodysplastic syndromes (LR-MDS), predominantly male (54%), overweight or obese (55%), White (96%), and non-Hispanic (89%), with a median age of 79 years.", "effective_dosage": "Not specified", "study_duration": "Median follow-up time of 17 months (IQR, 7-33)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:54.510257+00:00"}
{"study_id": 12971, "supplement_id": 1111, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the effectiveness, safety, and cost-effectiveness of short-acting (Eprex\u00ae) and long-acting (Aranesp\u00ae) ESAs in managing anemia in CKD patients.", "results_summary": "Aranesp was more effective than Eprex in achieving target hemoglobin levels (63.4% vs. 50.6%), with similar safety profiles and cost-saving advantages.", "population_specificity": "Adult Egyptian hemodialysis patients of either gender.", "effective_dosage": "Not specified", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:58.943867+00:00"}
{"study_id": 12970, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the risks of major adverse cardiovascular events (MACE) and all-cause mortality between short-acting and long-acting erythropoiesis-stimulating agents (ESAs) in hemodialysis patients.", "results_summary": "The study found no difference in MACE risk between short- and long-acting ESAs, but long-acting ESAs were associated with a lower risk of all-cause mortality compared to short-acting ESAs.", "population_specificity": "Medicare hemodialysis beneficiaries aged \u226518 years in the United States Renal Data System (mean age: 65 years, 45% females).", "effective_dosage": "Not specified", "study_duration": "Data analyzed from January 2015 to December 2017 (follow-up duration not explicitly stated).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:59.031993+00:00"}
{"study_id": 12969, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to elucidate the mechanisms behind the double-peak dynamics of erythroferrone (ERFE) in response to recombinant human erythropoietin (rHuEPO) and determine if early ERFE measurements could predict hemoglobin responses to rHuEPO.", "results_summary": "The study found that ERFE production involves an immediate release and a secondary peak mediated by transient iron deficiency, with early ERFE peak values predicting long-term hemoglobin responses to erythropoiesis-stimulating agents (ESAs). The PK/PD model confirmed these mechanisms and showed a stronger correlation between ERFE and hemoglobin peak values than observed values.", "population_specificity": "Rats (animal study)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:47:59.850408+00:00"}
{"study_id": 12972, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether anemia requiring RBC transfusion or ESAs in critically ill AKI patients undergoing CRRT was associated with adverse long-term outcomes after hospital discharge.", "results_summary": "Anemia requiring RBC transfusion or ESAs was not associated with increased cardiovascular events but was linked to higher all-cause mortality post-discharge in critically ill AKI patients on CRRT.", "population_specificity": "Critically ill adult patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT) for \u22653 days in South Korea (2010\u20132019).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:00.195983+00:00"}
{"study_id": 187854, "supplement_id": 1110, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of a combination of epigallocatechin-gallate (EGCG) and resveratrol on adipose tissue function and gene expression in overweight and obese humans.", "results_summary": "EGCG+RES did not affect adipocyte size but downregulated pathways related to adipogenesis, cell cycle, apoptosis, energy metabolism, oxidative stress, inflammation, and immune defense, suggesting reduced cell turnover in adipose tissue.", "population_specificity": "Overweight and obese humans (25 participants, 10 women).", "effective_dosage": "282 mg/d EGCG + 80 mg/d resveratrol.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:02.568105+00:00"}
{"study_id": 12973, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to investigate whether zinc supplementation affects the hematopoietic effect of HIF-PHIs (roxadustat) compared to ESAs (darbepoetin alfa) in hemodialysis patients.", "results_summary": "Zinc supplementation significantly increased ESA responsiveness (ERI) but had no significant effect on HIF-PHI responsiveness (HRI). Adequate zinc supplementation was recommended to mitigate concerns like vascular calcification and elevated serum copper during HIF-PHI use.", "population_specificity": "Thirty patients undergoing maintenance hemodialysis, with subsets treated with darbepoetin alfa (n=9) or roxadustat (n=9).", "effective_dosage": "Not specified", "study_duration": "Retrospective observation over 3 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:03.797739+00:00"}
{"study_id": 12974, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the outcomes of Erythropoiesis-Stimulating Agents (ESAs) in patients with lower-risk myelodysplastic syndromes (LR-MDS) and assess the predictive value of somatic mutations in treatment response.", "results_summary": "ESAs showed a 65% erythroid response rate, with serum erythropoietin levels <200 U/l significantly associated with higher response. Patients treated with ESAs had a median overall survival of 6.7 years versus 3.1 years for those receiving best supportive care. Somatic mutations (\u22653 genes) were linked to worse outcomes, including lower response rates and higher progression to acute myeloid leukemia.", "population_specificity": "Patients with lower-risk myelodysplastic syndromes (LR-MDS) from the SPRESAS study (n=722, with NGS data for 65).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:05.373822+00:00"}
{"study_id": 12975, "supplement_id": 1111, "safety_score": "30", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the RBC transfusion independence rate of imetelstat versus placebo in patients with RBC transfusion-dependent lower-risk myelodysplastic syndromes who were unresponsive to or ineligible for erythropoiesis-stimulating agents.", "results_summary": "Imetelstat demonstrated a significantly higher RBC transfusion independence rate (40%) compared to placebo (15%), with durable effects lasting approximately one year. However, it was associated with frequent grade 3-4 adverse events, including neutropenia (68%) and thrombocytopenia (62%).", "population_specificity": "Patients aged \u226518 years with ESA-relapsed, ESA-refractory, or ESA-ineligible lower-risk myelodysplastic syndromes (low or intermediate-1 risk per IPSS criteria).", "effective_dosage": "7.5 mg/kg administered as a 2-hour intravenous infusion every 4 weeks.", "study_duration": "Until disease progression, unacceptable toxic effects, or withdrawal of consent (median follow-up: 19.5 months for imetelstat, 17.5 months for placebo).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:06.410180+00:00"}
{"study_id": 12977, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate how dose regimens and other factors influence ESA resistance and to determine the role of precursor depletion in ESA resistance.", "results_summary": "The study found that instantaneous dose-adaptation can reduce ESA resistance, but up to 30% of healthy subjects still developed resistance. Subcutaneous administration and ESAs with longer half-lives led to stronger hemoglobin responses and less resistance. Increasing ESA dosage has a ceiling effect, with lower limits in anemic patients compared to healthy populations.", "population_specificity": "Healthy populations and anemic patients (specifically those with chronic kidney disease).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:07.938452+00:00"}
{"study_id": 12978, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to predict ESA resistance in non-dialysis-dependent chronic kidney disease patients using existing risk factors and serum test items.", "results_summary": "The study found that a combination of six existing risk factors and five serum test items could predict ESA resistance with moderate accuracy (AUC 0.736). The predictive model was derived from a post hoc analysis of a randomized controlled trial.", "population_specificity": "Anemic patients with non-dialysis-dependent chronic kidney disease and hyporesponsiveness to ESA.", "effective_dosage": "Not specified", "study_duration": "Landmark analysis at 3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:08.410014+00:00"}
{"study_id": 12976, "supplement_id": 1111, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to assess whether erythropoiesis-stimulating agents (ESA) administration impacts disease-free survival, overall survival, and time-to-distant recurrence in patients with HER2-positive early breast cancer receiving adjuvant anti-HER2 treatment.", "results_summary": "ESA administration was not associated with differences in disease-free survival, overall survival, or time-to-distant recurrence. Subgroup analyses suggested a potential benefit for premenopausal women receiving ESA, but adverse events were comparable between ESA and non-ESA groups.", "population_specificity": "Patients with HER2-positive early breast cancer (median age 54 years, 39.0% premenopausal, mostly with tumor size >2 cm, node-positive, and estrogen receptor-positive).", "effective_dosage": "Not specified", "study_duration": "Median follow-up was 6.1 years in the ESA group and 6.9 years in the non-ESA group.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:09.203538+00:00"}
{"study_id": 12979, "supplement_id": 1111, "safety_score": "30", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the risk of vision-threatening diabetic retinopathy (VTDR) in patients exposed to Erythropoiesis-Stimulating Agents (ESAs).", "results_summary": "The study found that ESAs were associated with a higher risk of VTDR and diabetic macular edema (DME) but not proliferative diabetic retinopathy (PDR). Both retrospective and self-controlled analyses supported these findings.", "population_specificity": "Non-proliferative diabetic retinopathy patients who were new users of an ESA from 2000 to 2022.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:09.894467+00:00"}
{"study_id": 12980, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of HIF-PHIs versus Erythropoiesis-Stimulating Agents (ESAs) on iron metabolism and inflammation in dialysis-dependent chronic kidney disease (DD-CKD) patients.", "results_summary": "HIF-PHIs showed no significant difference in transferrin saturation and ferritin levels compared to ESAs but increased iron, total iron-binding capacity, and transferrin levels while reducing hepcidin and intravenous iron requirements. HIF-PHIs maintained erythropoietic response independent of inflammation, suggesting potential as an alternative to ESAs in DD-CKD patients with iron deficiency and inflammation.", "population_specificity": "Dialysis-dependent chronic kidney disease (DD-CKD) patients.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:12.188847+00:00"}
{"study_id": 12981, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the effects of HIF-PHIs, ESAs, and placebo on iron metabolism and hemoglobin levels in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients.", "results_summary": "ESAs and HIF-PHIs both increased hemoglobin levels more than placebo, with desidustat showing the highest probability of increasing Hb. HIF-PHIs improved iron metabolism by reducing hepcidin and ferritin while increasing transferrin and total iron-binding capacity compared to ESAs.", "population_specificity": "Non-dialysis-dependent chronic kidney disease (NDD-CKD) patients.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:13.098893+00:00"}
{"study_id": 12982, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the long-term clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndrome (MDS) in a real-life setting.", "results_summary": "Epoetin alfa yielded significantly higher hemoglobin levels and lower transfusion needs compared to darbepoetin alfa at 36 and 48 months. Treatment response rates declined over time for both agents, with epoetin alfa showing better efficacy in low-risk MDS patients.", "population_specificity": "204 patients with low-risk or intermediate-1-risk MDS.", "effective_dosage": "Not specified", "study_duration": "Up to 48 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:14.443727+00:00"}
{"study_id": 12983, "supplement_id": 1111, "safety_score": "45", "efficacy_score": 65, "quality_score": 75, "study_goal": "To compare the efficacy and safety of different Erythropoiesis-Stimulating Agents (ESAs) in treating anemia in adults with chronic kidney disease (CKD).", "results_summary": "ESAs (epoetin alfa, epoetin beta, darbepoetin alfa) were generally effective in preventing blood transfusions compared to placebo, but their effects on mortality and cardiovascular events were uncertain. Some ESAs increased the odds of hypertension, while biosimilar ESAs had uncertain safety and efficacy profiles.", "population_specificity": "Adults with chronic kidney disease (CKD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:16.534156+00:00"}
{"study_id": 12985, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to understand the mechanism behind hemoglobin cycling in patients treated with erythropoiesis-stimulating agents (ESAs) and how physiological and treatment-related factors contribute to this phenomenon.", "results_summary": "The study found that hemoglobin cycling in ESA-treated patients arises from delayed physiological responses to ESAs and concurrent dose adjustments, with cycles influenced by factors like red blood cell lifespan and dosing schemes. The results suggest that cycling is a result of the interplay between patient physiology and treatment strategies, impacting ESA treatment design.", "population_specificity": "Patients with renal anemia treated with ESAs.", "effective_dosage": "Dynamically dosed (specific amounts not provided).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:17.718508+00:00"}
{"study_id": 12986, "supplement_id": 1111, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to compare the safety and risk of cancer-related adverse events between daprodustat and conventional erythropoiesis-stimulating agents (ESAs) in patients with anemia of chronic kidney disease (CKD) and dialysis patients.", "results_summary": "In non-dialysis patients (ASCEND-ND), the risk of cancer-related adverse events with daprodustat varied based on follow-up duration, showing higher risk with shorter follow-up but attenuation with longer intervals. No excess risk was observed in dialysis patients (ASCEND-D).", "population_specificity": "Patients with anemia of CKD (non-dialysis) and dialysis patients.", "effective_dosage": "Different dosing intervals (3/week, 1/week, every 2 or every 4 weeks) for ESA comparators.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:19.429659+00:00"}
{"study_id": 12984, "supplement_id": 1111, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to compare the safety and cardiovascular risks of roxadustat versus erythropoiesis-stimulating agents (ESAs) in patients with non-dialysis-dependent or incident dialysis-dependent chronic kidney disease (CKD) and anemia.", "results_summary": "Roxadustat showed comparable safety and cardiovascular risk profiles to ESAs, with no significant differences in major adverse cardiovascular events (MACE, MACE+), all-cause mortality, or treatment-emergent adverse events (TEAEs). Both treatments had similar rates of adverse events leading to discontinuation or death.", "population_specificity": "Men and women with non-dialysis-dependent (NDD) or incident dialysis-dependent (ID-DD) chronic kidney disease (CKD) and anemia.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:19.481999+00:00"}
{"study_id": 12987, "supplement_id": 1111, "safety_score": "85", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to assess the safety, efficacy, and survival impact of biosimilar ESA (B-ESA) in treating anemia in myelofibrosis (MF) patients.", "results_summary": "The study found that 80% of patients achieved anemia response (AR), with a median time to AR of 2.5 months. Survival was significantly better in AR patients, and B-ESA was well-tolerated, with only 2.5% discontinuing due to toxicity.", "population_specificity": "96 myelofibrosis (MF) patients with anemia.", "effective_dosage": "Not specified.", "study_duration": "Median follow-up of 43.8 months from diagnosis.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:19.530818+00:00"}
{"study_id": 12989, "supplement_id": 1111, "safety_score": "65", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to systematically review the efficacy and safety of Erythropoiesis-Stimulating Agents (ESAs) in children with chronic kidney disease (CKD), comparing different ESA types and administration modalities.", "results_summary": "All ESA preparations and administration methods were found to be efficacious, but higher doses were associated with increased risks, including hypertension and greater hazard of death. Secondary outcomes such as quality of life, growth, and cardiovascular function were also assessed, though evidence was limited.", "population_specificity": "Children with chronic and end-stage kidney disease.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:22.451992+00:00"}
{"study_id": 12990, "supplement_id": 1111, "safety_score": "45", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether combining erythropoiesis-stimulating agents (ESAs) with iron is more effective than using either treatment alone in reducing red blood cell transfusions and alleviating anemia in cancer patients.", "results_summary": "The study found that ESAs combined with iron (intravenous or oral) likely reduce the need for blood transfusions and improve hematological response but may increase on-study mortality, thromboembolic events, and hypertension. ESA alone showed similar efficacy but with a slightly increased risk of adverse events.", "population_specificity": "Cancer patients with anemia resulting from chemotherapy, radiotherapy, combination therapy, or the underlying malignancy.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:24.342232+00:00"}
{"study_id": 12988, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to investigate the relationship between erythropoiesis-stimulating agents (ESAs) and parathyroidectomy (PTX) in ESRD patients with secondary hyperparathyroidism (SHPT) and identify predictors for anemia improvement.", "results_summary": "The study found that PTX significantly reduced ESA requirements (from 41.6 to 10.3 unit/kg/week) and iron replacement therapy needs. Patients with low preoperative hemoglobin (\u226410 mg/dL) or low transferrin saturation (<25%) showed improved anemia post-PTX.", "population_specificity": "End-stage renal disease (ESRD) patients with secondary hyperparathyroidism (SHPT) who underwent parathyroidectomy (PTX).", "effective_dosage": "Median ESA dose pre-PTX: 41.6 (IQR, 0\u221291.2) unit/kg/week; post-PTX: 10.3 (IQR, 0\u221259.5) unit/kg/week.", "study_duration": "Retrospective analysis from July 2004 to December 2018 (14.5 years).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:24.364797+00:00"}
{"study_id": 12991, "supplement_id": 1111, "safety_score": "25", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to compare the incident cancer risk between ESA and non-ESA users with chronic kidney disease (CKD) or end-stage renal disease (ESRD).", "results_summary": "ESA usage was associated with a significantly higher risk of incident malignancy (HR 1.84) and genitourinary cancers (HR 12.55), with risk increasing with cumulative ESA dose. Clinicians are advised to minimize ESA dosage due to these risks.", "population_specificity": "Adults newly diagnosed with CKD or ESRD between 2000 and 2012 (n=98,748, with 7,115 after matching).", "effective_dosage": "Defined daily dose (DDD) used, but specific amounts not detailed.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:26.721242+00:00"}
{"study_id": 12995, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the association between serum trace metal concentrations and the administration/response to Erythropoiesis-Stimulating Agents (ESAs) in hemodialysis patients.", "results_summary": "The study found that trace metals, particularly manganese, are associated with ESA response, with altered Mn, Mo, Cd, Sn levels and their ratios characterizing ESA-treated patients. Patients with poor ESA response showed reduced Mn to Ni and Mn to Sb ratios.", "population_specificity": "110 hemodialysis patients with end-stage renal disease.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:28.671351+00:00"}
{"study_id": 12994, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to analyze the impact of biosimilar prescription targets on physician prescribing behavior for erythropoiesis-stimulating agents in Germany.", "results_summary": "Introducing biosimilar prescription targets increased biosimilar prescriptions by 6-20 percentage points across regions, with higher effects for high-volume prescribers. The increase in biosimilar share was driven by increased biosimilar use, with a nonsignificant decrease in original biologics prescriptions.", "population_specificity": "Physicians operating within the statutory health insurance system in ambulatory care across 7 German regions.", "effective_dosage": "Not specified", "study_duration": "2009 to 2015 (6 years)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:28.744445+00:00"}
{"study_id": 12992, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether combining erythropoiesis-stimulating agents (ESA) with iron (oral or IV) is more effective than iron alone in managing chemotherapy-induced anemia (CIA).", "results_summary": "The meta-analysis found that ESA combined with iron (oral or IV) significantly improved CIA outcomes, including hemoglobin levels, hematocrit, red blood cell count, and hematopoietic response rate, compared to iron alone. Subgroup analyses confirmed benefits regardless of iron administration method.", "population_specificity": "4,200 patients with chemotherapy-induced anemia (CIA), including participants from 34 Chinese and 7 English studies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:29.021273+00:00"}
{"study_id": 12993, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the cost-effectiveness of Ferric Pyrophosphate Citrate (FPC) and its impact on reducing the dose/use of Erythropoiesis-Stimulating Agents (ESAs) and IV iron therapy in dialysis patients.", "results_summary": "The study found no statistical difference in hemoglobin, ferritin, and iron saturation levels before and after FPC use. However, FPC significantly reduced the average weekly dose of darbepoetin alfa (from 52.74 \u03bcg to 39.27 \u03bcg) and the total dose of IV iron therapies, yielding substantial cost savings.", "population_specificity": "100 hemodialysis patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:29.741732+00:00"}
{"study_id": 12996, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 72, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the predictive factors for responsiveness to Erythropoiesis-Stimulating Agents (ESAs) in Asian patients with low-risk myelodysplastic syndromes (MDS).", "results_summary": "The study found that 46.8% of patients responded to ESAs, with responders having significantly lower baseline erythropoietin (EPO) levels. Responders also showed a higher 5-year overall survival rate compared to non-responders.", "population_specificity": "Asian patients with low-risk MDS (median age 77 years, 44.7% male).", "effective_dosage": "Median dosage of 30,000 units per week in responders.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:32.674988+00:00"}
{"study_id": 12997, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to estimate the excess costs associated with needle-based administration of ESAs for treating anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients in the US in 2019.", "results_summary": "The study found that needle-based ESA administration incurred $2.5 billion in annual excess costs, primarily from in-clinic administration (94.4%). Direct healthcare costs were the largest contributor (54.9%), followed by patient and caregiver productivity losses and transportation costs.", "population_specificity": "Patients with anemia and non-dialysis-dependent chronic kidney disease (NDD-CKD) in the US.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:33.599060+00:00"}
{"study_id": 12999, "supplement_id": 1111, "safety_score": "60", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to assess the effectiveness of ESAs in treating anemia in cancer patients and evaluate the associated cardiovascular risks and impact on prognosis.", "results_summary": "ESAs effectively reduced the need for blood transfusions and increased hemoglobin levels in anemic cancer patients but were associated with cardiovascular adverse effects, particularly venous thromboembolism, without significantly affecting overall survival.", "population_specificity": "Anemic cancer patients (10,738 participants across 17 RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:34.566262+00:00"}
{"study_id": 12998, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the safety and efficacy of molidustat versus darbepoetin alfa in maintaining hemoglobin levels in Japanese patients with renal anemia not undergoing dialysis and previously treated with ESAs.", "results_summary": "Molidustat was noninferior to darbepoetin in maintaining hemoglobin levels within the target range (11.0-13.0 g/dL). Safety profiles were comparable, though molidustat had a higher incidence of serious adverse events (32.9% vs. 26.8%) and two deaths were reported in the molidustat group.", "population_specificity": "Japanese patients with anemia due to chronic kidney disease (stages 3-5) not undergoing dialysis and previously treated with ESAs.", "effective_dosage": "Molidustat 25 mg or 50 mg once daily; darbepoetin alfa administered subcutaneously once every 2 or 4 weeks.", "study_duration": "52 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:35.869837+00:00"}
{"study_id": 13000, "supplement_id": 1111, "safety_score": "30", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to examine the de-adoption of erythropoiesis-stimulating agents (ESA) in anemia treatment among CKD patients following new evidence of harm and ineffectiveness, and the FDA's revised safety warning.", "results_summary": "Use of ESA declined post-TREAT trial and FDA revision, with nephrologists being more responsive to new evidence than primary care physicians. No consistent changes were observed across insurance groups or physician demographics.", "population_specificity": "Patients with chronic kidney disease (CKD) in commercial, Medicare Advantage, and Medicare fee-for-service populations.", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:37.619991+00:00"}
{"study_id": 13003, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if oxidative stress parameters could predict the response to erythropoiesis-stimulating agents (ESAs) in lower-risk myelodysplastic syndromes (MDS) patients.", "results_summary": "The study found that ESA responders had lower levels of plasma peroxides, cellular GSH, and GR activity, as well as a lower peroxides/TAS ratio and higher NFE2L2 gene expression. Plasmatic peroxides were identified as the most accurate biomarker of ESA response, with high sensitivity and specificity.", "population_specificity": "66 lower-risk MDS patients, 44 of whom were treated with ESA.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:38.551941+00:00"}
{"study_id": 13002, "supplement_id": 1111, "safety_score": "30", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to investigate the relationships among ESA dosage, erythropoietin resistance index (ERI) scores, and all-cause mortality in Chinese hemodialysis patients.", "results_summary": "Higher ESA dosages (>10,000.0 IU/week) and higher ERI scores (>12.80) were significantly associated with increased all-cause mortality. Patients administered high ESA dosages had worse survival outcomes compared to those on low dosages.", "population_specificity": "Chinese hemodialysis patients from 16 blood purification centers (n = 824).", "effective_dosage": "ESA dosages grouped into quartiles, with >10,000.0 IU/week identified as a high-risk threshold.", "study_duration": "Patients were followed from 2011-2015 until December 31, 2016.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:39.323744+00:00"}
{"study_id": 13006, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of preoperative iron supplementation with or without erythropoiesis-stimulating agents (ESAs) on reducing red blood cell (RBC) transfusion requirements in anemic patients scheduled for elective surgery.", "results_summary": "The study found that iron monotherapy may not reduce RBC transfusion needs (low-certainty evidence), but iron combined with ESAs probably reduces the number of patients and units transfused (moderate-certainty evidence). Uncertainty remains about the differential effects of IV vs. oral iron and the impact on patients requiring multiple transfusions (very low-certainty evidence).", "population_specificity": "Anemic patients of any cause scheduled for elective surgery.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:43.980874+00:00"}
{"study_id": 13004, "supplement_id": 1111, "safety_score": "80", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in treating anemia in Japanese patients with chronic kidney disease on hemodialysis not receiving erythropoiesis-stimulating agents.", "results_summary": "Vadadustat increased and maintained hemoglobin levels within the target range (10.0-12.0 g/dL), with a mean Hb of 10.75 g/dL at Weeks 20 and 24. The treatment was generally well-tolerated, with shunt stenosis being the most common adverse event (25.0%) and mild adverse drug reactions occurring in 8.3% of patients.", "population_specificity": "Japanese patients with chronic kidney disease-associated anemia on hemodialysis not receiving erythropoiesis-stimulating agents (n=24).", "effective_dosage": "Starting dose of 300 mg/day, adjusted to achieve target hemoglobin range.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:44.139721+00:00"}
{"study_id": 13007, "supplement_id": 1111, "safety_score": "70", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to summarize the role of various erythropoiesis-stimulating agents in treating anemia by reviewing their clinical characteristics, efficacy, and safety.", "results_summary": "The study found that erythropoiesis-stimulating agents vary in clinical characteristics and stability due to chemical modifications, influencing their half-life, receptor affinity, and immune response. These agents are categorized as short-acting or long-acting, with efficacy and safety differing based on individual patient characteristics and anemia etiology.", "population_specificity": "Patients with anemia due to chronic kidney disease, anticancer drugs, myelodysplastic syndrome, and other conditions.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:45.235891+00:00"}
{"study_id": 13008, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to examine disparities in the use of ESAs and blood transfusions after a Medicare reimbursement policy change, focusing on gender and racial/ethnic differences.", "results_summary": "The policy change led to a 50% reduction in ESA use and a 10% increase in blood transfusions, with greater reductions in females (60%) than males (30%) and a 50% increase in transfusions among African Americans/Blacks.", "population_specificity": "Cancer patients (treatment group) and chronic kidney disease patients (control group).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:45.993266+00:00"}
{"study_id": 13005, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether different erythropoiesis-stimulating agents (EPO, DA, CERA) affect vascular mediators like endothelial progenitor cells (EPCs) and other biomarkers in dialysis patients.", "results_summary": "Only EPO significantly increased circulating EPCs in a dose-dependent manner, while DA and CERA had no effect. Serum levels of VEGF, MMP-2, and hs-CRP remained unchanged across all groups, and CERA was associated with decreased serum ferritin.", "population_specificity": "51 dialysis patients (13 treated with EPO, 16 with DA, 12 with CERA, 10 with no ESAs).", "effective_dosage": "EPO (5290.4 \u00b1 586.9 IU/week), DA (42.9 \u00b1 4.3 \u00b5g/week), CERA (40.5 \u00b1 4.1 \u00b5g/week).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:46.062984+00:00"}
{"study_id": 13009, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the direct healthcare costs of CKD patients treated with ESAs and assess potential savings from increased biosimilar use and prevention of inappropriate ESA dispensing.", "results_summary": "The study found that ESA-related costs constituted a significant portion of total healthcare costs for CKD patients, with potential savings achievable through biosimilar substitution and reducing inappropriate ESA use. Inappropriate ESA dispensing was observed in 9% of new users and 62% during maintenance therapy.", "population_specificity": "Chronic kidney disease (CKD) patients in five large Italian geographic areas, stratified by CKD stage (I-V and dialysis).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:47.507943+00:00"}
{"study_id": 13001, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to review the cost-effectiveness of preoperative iron and/or Erythropoiesis-Stimulating Agents (ESAs) in anaemic elective surgery patients and update existing economic evaluations with recent data.", "results_summary": "The study found that cost-effectiveness of preoperative iron remains uncertain, while routine preoperative ESA therapy was not cost-effective, with cost per (QA)LY gained ranging from 3.5-120 million GBP or CAD.", "population_specificity": "Anaemic elective surgery patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:49.195443+00:00"}
{"study_id": 13012, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to assess adherence to ESA treatment in CKD patients with anemia and analyze its relationship to treatment response.", "results_summary": "The study found good adherence (89.6%) to ESA treatment, with 87% of patients achieving Hb targets. Response to ESA was independent of adherence levels.", "population_specificity": "198 patients with chronic kidney disease (CKD) and associated anemia.", "effective_dosage": "Not specified", "study_duration": "2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:51.108819+00:00"}
{"study_id": 13011, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 40, "quality_score": 85, "study_goal": "The researchers aimed to determine whether erythropoiesis-stimulating agents (ESAs) reduced the need for red blood cell transfusions and improved hemoglobin levels in critically ill ICU patients, while also assessing adverse events and mortality.", "results_summary": "ESAs resulted in a small reduction in transfusion rates and a trivial increase in hemoglobin, both of questionable clinical relevance, with no significant impact on adverse events or mortality.", "population_specificity": "Critically ill adult patients admitted to the intensive care unit (ICU).", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:52.287894+00:00"}
{"study_id": 13013, "supplement_id": 1111, "safety_score": "30", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of erythropoiesis-stimulating agents (ESAs) in breast cancer patients, focusing on mortality, transfusion requirements, and thromboembolic events.", "results_summary": "The study found that ESAs reduced transfusion needs but increased mortality and thromboembolic risks, with varying outcomes among different ESA types (epoetin alfa, epoetin beta, darbepoetin alfa). Tumor progression was notably high with epoetin alfa and beta but absent with darbepoetin alfa.", "population_specificity": "Breast cancer patients (6,849 participants across 11 RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:54.803666+00:00"}
{"study_id": 13015, "supplement_id": 1111, "safety_score": "30", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the utilization trends and safety impact of Erythropoiesis-Stimulating Agents (ESAs) in treating chemotherapy-induced anemia (CIA) following regulatory changes.", "results_summary": "ESA use for CIA declined sharply after 2007 due to safety concerns and reimbursement restrictions, with darbepoetin use decreasing by 95% and epoetin by 90% by 2012. Transfusion rates among CIA patients increased 2.2-fold post-2008, suggesting reduced ESA reliance.", "population_specificity": "Commercially insured patients with lung, colorectal, or breast cancer (2001-2012).", "effective_dosage": "Epoetin: 244,979 units (2003) vs. 196,216 units (2012); Darbepoetin: 262 \u03bcg (2003) vs. 467 \u03bcg (2012).", "study_duration": "Up to 6 months after chemotherapy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:57.112238+00:00"}
{"study_id": 13016, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the effectiveness of mixed-dilution hemodiafiltration (Mixed HDF) versus post-dilution hemodiafiltration (Post-HDF) in reducing erythropoiesis-stimulating agent (ESA) requirements in dialysis patients.", "results_summary": "Mixed HDF significantly reduced darbepoetin alfa requirements by 29% compared to Post-HDF, with lower ESA resistance and consistent efficacy across treatment sequences. The study concluded that Mixed HDF could mitigate high ESA dose side effects and offer economic benefits.", "population_specificity": "120 prevalent dialysis patients from 6 dialysis centers.", "effective_dosage": "Darbepoetin alfa doses varied, with average monthly requirements of 23.8 \u00b5g for Mixed HDF and 38.4 \u00b5g for Post-HDF.", "study_duration": "Six months per treatment sequence (total 12 months for cross-over design).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:58.639301+00:00"}
{"study_id": 13014, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to assess the effectiveness and safety of early administration of erythropoiesis-stimulating agents (EPO and Darbe) in reducing red blood cell transfusions, adverse neurological outcomes, and feeding intolerance (including necrotising enterocolitis) in preterm and/or low birth weight infants.", "results_summary": "Early ESA administration reduced the need for red blood cell transfusions, decreased the incidence of necrotising enterocolitis, and improved some neurodevelopmental outcomes, though benefits were modest and clinical importance varied. No significant difference was found in stage \u2265 3 retinopathy of prematurity, and mortality was unaffected, but rates of intraventricular haemorrhage and periventricular leukomalacia were reduced.", "population_specificity": "Preterm and/or low birth weight infants (enrolled 3,643 infants across 34 studies).", "effective_dosage": "Low (\u2264 500 IU/kg/week) and high (> 500 IU/kg/week) doses of EPO, with iron supplementation categorized as none, low (\u2264 5 mg/kg/d), or high (> 5 mg/kg/d).", "study_duration": "Intervention initiated before eight days after birth (specific duration not detailed in abstract).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:58.992577+00:00"}
{"study_id": 13010, "supplement_id": 1111, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to assess the efficacy and safety of intravenous ferric carboxymaltose (FCM) for treating cancer-induced anemia in patients receiving active chemotherapy.", "results_summary": "Intravenous FCM significantly increased hemoglobin levels in patients with absolute or functional iron deficiency (groups I and II) by week 12, with most improvements observed by week 3. No clinically significant adverse events were reported, though asymptomatic hypophosphatemia occurred in 46.4% of patients.", "population_specificity": "Adult cancer patients on active chemotherapy with hemoglobin levels \u226411.0 g/dL, divided into groups based on iron deficiency status.", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:59.458897+00:00"}
{"study_id": 13017, "supplement_id": 1111, "safety_score": "65", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess the effectiveness and safety of late initiation of erythropoiesis-stimulating agents (ESAs) in reducing red blood cell transfusions in preterm or low birth weight infants.", "results_summary": "Late administration of EPO reduced the need for one or more RBC transfusions and the number of transfusions per infant but did not significantly affect the total volume transfused. There was a trend toward increased risk for retinopathy of prematurity (ROP), but no significant differences in other adverse outcomes like mortality or necrotising enterocolitis.", "population_specificity": "Preterm (< 37 weeks) or low birth weight (< 2500 grams) neonates.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Intervention started between eight and 28 days after birth (duration not explicitly stated).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:48:59.487823+00:00"}
{"study_id": 13019, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the frequency and predictors of switching between biosimilar and originator ESAs during the first year of treatment in patients with chronic kidney disease or chemotherapy-related anemia.", "results_summary": "Switching between ESAs was frequent (15.5% of users), with single switches being more common than multiple or backward switches. Predictors of switching included cumulative transfusions, iron preparations, hyperparathyroidism (in cancer patients), and CKD severity (in CKD patients).", "population_specificity": "Patients with chronic kidney disease or chemotherapy-related anemia from six large Italian geographic areas.", "effective_dosage": "Not specified", "study_duration": "First year of treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:00.980595+00:00"}
{"study_id": 13022, "supplement_id": 1111, "safety_score": "65", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine whether Erythropoiesis-Stimulating Agents (ESAs) reduce mortality in critically ill adult patients admitted to the ICU.", "results_summary": "ESA therapy was associated with lower in-hospital mortality (12.6% vs. 15.4%) compared to the control group, with no significant difference in serious adverse events or thromboembolic events. The evidence, however, comes from studies of mainly low or unclear quality.", "population_specificity": "Critically ill adult patients admitted to the ICU.", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:06.985323+00:00"}
{"study_id": 13021, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare cardiovascular outcomes and all-cause mortality between monthly methoxy polyethylene glycol-epoetin beta and shorter-acting erythropoiesis-stimulating agents (epoetin alfa/beta and darbepoetin alfa) in patients with anemia of chronic kidney disease (CKD).", "results_summary": "The study found that methoxy polyethylene glycol-epoetin beta was noninferior to shorter-acting agents in terms of major adverse cardiovascular events and all-cause mortality, with no significant differences between the two treatment groups. Results were consistent across subgroups, including dialysis patients and those in correction or maintenance treatment settings.", "population_specificity": "Patients with anemia of chronic kidney disease (CKD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Median follow-up of 3.4 years (maximum 8.4 years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:07.170131+00:00"}
{"study_id": 13024, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 80, "quality_score": 90, "study_goal": "To update recommendations for the use of erythropoiesis-stimulating agents (ESAs) in patients with cancer, focusing on safety, efficacy, and appropriate usage.", "results_summary": "The study found that ESAs (including biosimilars) are effective in reducing the need for RBC transfusions in patients with chemotherapy-associated anemia when hemoglobin levels drop below 10 g/dL. Adding iron to ESA treatment may improve hematopoietic response and further reduce transfusion likelihood.", "population_specificity": "Patients with cancer, specifically those with chemotherapy-associated anemia or selected patients with myelodysplastic syndromes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:08.517675+00:00"}
{"study_id": 13018, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to review the adverse effects and current patterns of red blood cell transfusion use in CKD patients, while exploring the limitations and clinical scenarios where Erythropoiesis-Stimulating Agents (ESAs) are ineffective.", "results_summary": "The study highlights that despite the availability of ESAs, red blood cell transfusions remain necessary in certain clinical settings (e.g., active bleeding, bone marrow resistance, infections) where ESAs are ineffective or underutilized. It also discusses the need to optimize transfusion strategies without compromising patient safety.", "population_specificity": "Patients with chronic kidney disease (CKD) at all stages.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:09.044309+00:00"}
{"study_id": 13025, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to assess the efficacy of combining erythropoiesis-stimulating agents (ESA) with granulocyte colony-stimulating factor (G-CSF) for treating anemia in lower-risk myelodysplastic syndromes.", "results_summary": "The study found that combining G-CSF with low-/standard-dose ESA improved erythroid response rates (33-40% to 65-73%), but results were mixed when G-CSF was added to full-dose ESA (12-71% vs. 35-74%). The analysis supports additional efficacy for low-/standard-dose ESA combinations but remains inconclusive for full-dose combinations.", "population_specificity": "Anemic patients with lower-risk myelodysplastic syndromes.", "effective_dosage": "Low-/standard-dose ESA (10,000-30,000 rHuEPO equivalents/week); full-dose ESA (60,000-80,000 rHuEPO equivalents/week).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:10.542967+00:00"}
{"study_id": 13023, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 80, "quality_score": 90, "study_goal": "To update recommendations for the use of erythropoiesis-stimulating agents (ESAs) in patients with cancer, focusing on safety, efficacy, and appropriate usage.", "results_summary": "The study found that ESAs (including biosimilars) are effective in reducing the need for RBC transfusions in patients with chemotherapy-associated anemia when hemoglobin levels decline below 10 g/dL. Adding iron to ESA treatment may improve hematopoietic response and further reduce transfusion likelihood.", "population_specificity": "Patients with cancer, specifically those with chemotherapy-associated anemia or selected patients with myelodysplastic syndromes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:10.749741+00:00"}
{"study_id": 13026, "supplement_id": 1111, "safety_score": "65", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the effectiveness and safety of late initiation of erythropoiesis-stimulating agents (ESAs) in reducing red blood cell transfusions in preterm or low birth weight infants.", "results_summary": "Late administration of EPO reduced the need for one or more RBC transfusions and the number of transfusions per infant but did not significantly reduce the total volume of blood transfused. There was a trend toward increased risk for retinopathy of prematurity (ROP), but no significant differences in other adverse outcomes like mortality or necrotising enterocolitis.", "population_specificity": "Preterm infants (< 37 weeks) or low birth weight neonates (< 2500 grams).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Intervention started between eight and 28 days after birth (duration not further specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:11.219010+00:00"}
{"study_id": 13027, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate adherence, switch rates, and costs of different erythropoietin-stimulating agents (originators vs. biosimilars) one year after treatment initiation.", "results_summary": "Adherence was slightly higher for originators (0.84) than biosimilars (0.76), but the difference was not statistically significant (p=0.3241). Biosimilars were significantly cheaper, costing \u20ac2587 per patient annually compared to \u20ac7365 for originators.", "population_specificity": "277 patients (200 on originators, 77 on biosimilars).", "effective_dosage": "Not specified.", "study_duration": "1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:16.972821+00:00"}
{"study_id": 13028, "supplement_id": 1111, "safety_score": "45", "efficacy_score": 60, "quality_score": 80, "study_goal": "The researchers aimed to assess the risk of venous thromboembolism (VTE), myocardial infarction (MI), and stroke associated with Erythropoiesis-Stimulating Agents (ESAs) in patients with multiple myeloma (MM) and myelodysplastic syndrome (MDS).", "results_summary": "ESA use was associated with an increased risk of stroke in MDS patients and a higher risk of all cardiovascular events in MM patients, though confidence intervals included equivalence for some outcomes. Incidence rates for VTE, MI, and stroke varied between MDS and MM patients with and without ESA treatment.", "population_specificity": "Patients with multiple myeloma (MM) and myelodysplastic syndrome (MDS) diagnosed in Denmark between 2004-2013.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:17.059789+00:00"}
{"study_id": 13029, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to compare clinical, economic, and health-related quality of life outcomes for short-acting and long-acting ESAs in patients with chronic kidney disease-induced anemia (CKD-IA) and chemotherapy-induced anemia (CIA).", "results_summary": "The study found little difference in efficacy, HRQoL, and safety outcomes among ESA types, suggesting cost-effectiveness and market price may influence agent choice. Comparative studies and costing models incorporating biosimilars are needed to determine cost-effectiveness.", "population_specificity": "Patients with chronic kidney disease-induced anemia (CKD-IA) and chemotherapy-induced anemia (CIA).", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:17.403281+00:00"}
{"study_id": 13030, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the effectiveness of Erythropoiesis-Stimulating Agents (ESAs) in treating anemia in low-risk myelodysplastic syndrome (MDS) patients and explore options for ESA-resistant cases.", "results_summary": "ESAs, with or without granulocyte colony-stimulating factor, induced erythroid response rates in 40-50% of lower-risk anemic MDS patients, with a median response duration of 24 months. The study highlights ESAs' role in inhibiting erythroid cell apoptosis and improving erythropoiesis.", "population_specificity": "Lower-risk myelodysplastic syndrome (MDS) patients with anemia (Hb < 100 g/L).", "effective_dosage": "Not specified", "study_duration": "Median response duration of 24 months (intervention duration not explicitly stated).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:18.763436+00:00"}
{"study_id": 13033, "supplement_id": 1111, "safety_score": "85", "efficacy_score": 90, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy and safety of biosimilar erythropoiesis-stimulating agents (ESAs) versus originator ESAs in patients with chronic kidney disease (CKD).", "results_summary": "The study found that biosimilar ESAs resulted in significantly greater hemoglobin increases compared to originator ESAs at 3, 6, and 12 months, with similar safety profiles. The data contradicted the common perception that biosimilars are less effective or safe than originators.", "population_specificity": "Patients with chronic kidney disease (CKD) on conservative treatment from nine Italian healthcare centers.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:20.506436+00:00"}
{"study_id": 13032, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 65, "study_goal": "The researchers aimed to assess the cost impact of administering erythropoiesis-stimulating agents once every 4 weeks compared to one to three times a week for treating anaemia in dialysis patients.", "results_summary": "The study found that administering methoxy polyethylene glycol-epoetin beta every 4 weeks saved medical and nurse time (7 and 15 days per year, respectively) and reduced costs by \u20ac59,960 annually for 40 haemodialysis patients. The approach was deemed beneficial for the hospital.", "population_specificity": "27 patients undergoing haemodialysis at a university hospital in Angers, France (2009\u20132013).", "effective_dosage": "Once every 4 weeks (specific dosage not mentioned).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:20.887595+00:00"}
{"study_id": 13031, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the safety and efficacy of vadadustat, an oral hypoxia-inducible factor prolyl-4-hydroxylase inhibitor, in maintaining hemoglobin levels in hemodialysis patients previously treated with epoetin alfa.", "results_summary": "Vadadustat maintained stable hemoglobin levels without significant changes from baseline, with no serious adverse events attributed to the drug. Common adverse events included nausea, diarrhea, and vomiting, but no deaths occurred.", "population_specificity": "94 subjects receiving hemodialysis, previously maintained on epoetin alfa.", "effective_dosage": "300 mg once daily (QD), 450 mg QD, or 450 mg thrice weekly (TIW).", "study_duration": "15-16 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:21.161096+00:00"}
{"study_id": 13020, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to review biosimilar development and focus on the first approved biosimilar epoetin in the United States, epoetin alfa-epbx.", "results_summary": "The abstract highlights the importance of erythropoietin analogues in managing anemia in advanced CKD and notes the introduction of biosimilar agents to reduce costs, with biosimilar epoetin being used in Europe since 2007.", "population_specificity": "Patients with advanced chronic kidney disease (CKD).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:22.406322+00:00"}
{"study_id": 13034, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether neonatal ESA treatment in premature infants would normalize neurometabolite levels by 4-6 years of age.", "results_summary": "The study found no significant differences in brain metabolite levels between prematurely born children treated with ESAs or placebo and healthy term controls, suggesting earlier differences may have normalized or were too small to detect.", "population_specificity": "Prematurely born infants (500-1,250 g birth weight) and healthy term controls.", "effective_dosage": "Not specified", "study_duration": "During neonatal hospitalization (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:26.259892+00:00"}
{"study_id": 13036, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to assess the impact of unreported and unpublished data from clinical study reports (CSRs) on the effects of erythropoiesis-stimulating agents (ESAs) on quality of life (QoL) in cancer patients and to identify discrepancies between publicly available data and CSRs.", "results_summary": "The study found that access to CSRs reduced reporting biases for QoL outcomes, but discrepancies between public and CSR data had little impact on pooled effect estimates. Including unpublished data reduced the pooled effect of ESAs on QoL to below a clinically important difference.", "population_specificity": "Cancer patients", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:26.396590+00:00"}
{"study_id": 13038, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate factors affecting ferritin levels and erythropoietin resistance index in hemodialysis patients treated with ferric citrate hydrate, focusing on the role of erythropoiesis-stimulating agents.", "results_summary": "The study found that ferric citrate hydrate dose and erythropoiesis-stimulating agent reduction were strongly correlated with ferritin elevation, leading to a decreased erythropoietin resistance index, particularly in the group with the lowest baseline ferritin levels.", "population_specificity": "Hemodialysis patients in a Japanese phase III clinical trial.", "effective_dosage": "Not specified", "study_duration": "52 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:29.443376+00:00"}
{"study_id": 13040, "supplement_id": 1111, "safety_score": "65", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the benefits and risks of Erythropoiesis-Stimulating Agents (ESAs) in treating renal anemia, including newer therapeutic options and their potential advantages over conventional ESAs.", "results_summary": "The study found that ESAs improve hemoglobin levels up to 10-11 g/dL with clinical benefits, but higher doses may increase cerebro-cardiovascular risks. Newer therapies, such as activin inhibitors and hypoxia-inducible factor prolyl hydroxylase inhibitors, show promise for broader therapeutic effects, including reduced mortality and improved mineral metabolism.", "population_specificity": "Patients with chronic kidney disease and associated renal anemia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:30.006222+00:00"}
{"study_id": 13039, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of erythropoiesis-stimulating agents (ESAs) in improving anemia and quality of life in lower-risk myelodysplastic syndromes (MDS) patients.", "results_summary": "ESAs yielded favorable responses in about half of the patients, though responses were often short-lived. Novel TGF-\u03b2 superfamily inhibitors showed promise in alleviating anemia by stimulating erythroid differentiation in ESA-refractory patients.", "population_specificity": "Patients with lower-risk myelodysplastic syndromes (MDS) affected by chronic anemia and fatigue.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:30.395089+00:00"}
{"study_id": 13041, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the time and cost of preparing and administering short-acting versus long-acting ESAs in hemodialysis patients with CKD-related anemia.", "results_summary": "The study found that switching from short-acting to long-acting ESAs reduced preparation and administration time costs by 73-80%, resulting in annual savings of AUD$2,591 to AUD$5,914 per unit if all patients used long-acting ESAs.", "population_specificity": "Patients on facility-based hemodialysis with anemia due to chronic kidney disease in four Australian HD units.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:30.612328+00:00"}
{"study_id": 13037, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to assess the effectiveness and safety of early administration of erythropoiesis-stimulating agents (EPO and Darbe) in reducing red blood cell transfusions, adverse neurological outcomes, and feeding intolerance (including necrotising enterocolitis) in preterm and/or low birth weight infants.", "results_summary": "Early ESA administration reduced the need for red blood cell transfusions, decreased rates of necrotising enterocolitis, and improved neurodevelopmental outcomes at 18-22 months. However, the clinical importance of these reductions was limited, and donor exposure was not significantly avoided.", "population_specificity": "Preterm and/or low birth weight infants.", "effective_dosage": "Low (\u2264 500 IU/kg/week) and high (> 500 IU/kg/week) doses of EPO, with iron supplementation categorized as none, low (\u2264 5 mg/kg/d), or high (> 5 mg/kg/d).", "study_duration": "Initiated before eight days after birth (specific duration not detailed).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:30.718957+00:00"}
{"study_id": 13042, "supplement_id": 1111, "safety_score": "45", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to assess the harms and effects of off-label use of erythropoiesis-stimulating agents (ESAs) in critically-ill people, comparing them to placebo, no treatment, or other interventions.", "results_summary": "The study found low-quality evidence suggesting ESAs may reduce mortality in critically-ill patients, but the risk of adverse events and venous thromboembolism remains unclear due to very low-quality evidence. Most studies did not evaluate harm as a primary outcome.", "population_specificity": "Critically-ill people", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:34.681502+00:00"}
{"study_id": 13043, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in cancer patients receiving myelosuppressive chemotherapy following regulatory and reimbursement actions.", "results_summary": "ESA use decreased substantially across all tumor types, transfusion use increased, and the median number of ESA administrations declined. Patients initiating ESA therapy were more likely to have hemoglobin levels <10 g/dL in recent years, consistent with current product labeling.", "population_specificity": "Cancer patients (breast, colorectal, lung, multiple myeloma, non-Hodgkin lymphoma, ovarian, or prostate cancer) receiving myelosuppressive chemotherapy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:35.302170+00:00"}
{"study_id": 13035, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness and cardiovascular safety of Erythropoiesis-Stimulating Agents (ESAs) in treating elderly patients with anemia of unknown etiology (AUE).", "results_summary": "The study found that ESAs showed a nonstatistically significant but quantitatively better response in AUE (47%) and CKD (54%) compared to other etiologies (22%). No statistically significant difference in cardiovascular events was observed between treated and untreated groups.", "population_specificity": "Elderly anemic patients older than 60 years with measured erythropoietin levels between 2005 and 2013 at a single center.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:35.637911+00:00"}
{"study_id": 13046, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the causes and implications of hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in non-dialysis CKD patients and evaluate its correlation with CKD progression and cardiovascular disease events.", "results_summary": "The study is ongoing and aims to clarify markers of ESA hyporesponsiveness and their relationship with renal and CVD events, but no specific results are reported yet.", "population_specificity": "Non-dialysis chronic kidney disease (CKD) patients with renal anemia and eGFR below 60 mL/min/1.73 m\u00b2.", "effective_dosage": "Not specified", "study_duration": "96 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:39.135416+00:00"}
{"study_id": 13047, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine whether erythropoiesis-stimulating agents (ESAs) improve brain development in preterm infants by analyzing cortical thickness, surface area, and white matter organization via MRI.", "results_summary": "The study found no significant overall effect of ESAs on cortical thickness, surface area, or fractional anisotropy (FA), but ESA-treated girls showed greater FA increases. FA correlated with Full-Scale IQ and Verbal IQ, though not among preterm children alone.", "population_specificity": "Former preterm infants treated with ESAs or placebo, and healthy term controls.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:39.744593+00:00"}
{"study_id": 13044, "supplement_id": 1111, "safety_score": "60", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to review the indications and controversies surrounding the use of Erythropoiesis-Stimulating Agents (ESAs) in treating anemia in elderly patients with oncological and non-oncological diseases.", "results_summary": "The study found that ESA use in elderly patients with advanced disease is limited due to inconsistent recommendations and lack of large-scale prospective trials. Consensus exists for ESA use in advanced chronic kidney disease, non-myeloid cancer patients without curative intent, and myelodysplastic syndrome patients responsive to transfusional support, but risks of mortality and cardioembolic morbidity are increased.", "population_specificity": "Elderly patients with oncological and non-oncological diseases, including chronic kidney disease, non-myeloid cancer, and myelodysplastic syndrome.", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:39.761119+00:00"}
{"study_id": 13045, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether levocarnitine injections could reduce the required dose of erythropoiesis-stimulating agents (ESAs) and improve ESA therapy response in hemodialysis patients with renal anemia.", "results_summary": "The study found that levocarnitine administration significantly reduced the ESA dose needed to maintain target hemoglobin and hematocrit levels and improved the erythropoietin responsiveness index (ERI) at 6 and 12 months compared to the control group.", "population_specificity": "Hemodialysis patients with renal anemia.", "effective_dosage": "1,000 mg levocarnitine injection 3 times weekly after hemodialysis sessions.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:40.285742+00:00"}
{"study_id": 13048, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the impact of Erythropoiesis-Stimulating Agents (ESA) on HbA1c and fructosamine levels in diabetic and non-diabetic CKD5 patients undergoing haemodialysis.", "results_summary": "ESA therapy inversely affected HbA1c levels, with a dose-dependent decrease (0.6% per 10,000 IU/week escalation), but had no effect on fructosamine. Both epoetin \u03b1 and C.E.R.A. achieved comparable Hb targets, though C.E.R.A. showed better correlation and efficacy over longer dose intervals.", "population_specificity": "102 CKD5 patients (with and without diabetes mellitus) undergoing haemodialysis.", "effective_dosage": "Epoetin \u03b1 (n=48) and methoxy polyethylene glycol epoetin beta (C.E.R.A.; n=54) \u2013 specific dosages not detailed.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:40.971715+00:00"}
{"study_id": 13049, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to analyze outcomes after ESA failure in patients with non-del(5q) lower-risk MDS and evaluate the effect of second-line treatments on disease progression and overall survival.", "results_summary": "The study found a 61.5% erythroid response rate to ESAs with a median response duration of 17 months. Primary ESA failure was associated with a higher risk of AML progression, but none of the second-line treatments (HMAs, LEN, or MISC) significantly improved overall survival.", "population_specificity": "Patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) treated with ESAs (n=1,698).", "effective_dosage": "Not specified", "study_duration": "Median response duration was 17 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:44.380273+00:00"}
{"study_id": 13051, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of biosimilar erythropoiesis-stimulating agents (ESAs) in treating anemia in chronic kidney disease patients, comparing their safety and efficacy to reference biologics.", "results_summary": "The abstract highlights that biosimilars have been successfully used in Europe for over a decade without unusual effects compared to reference biologics, suggesting potential for similar success in the US market. It also notes the opportunity for biosimilar EPO development following patent expiries of existing biologics.", "population_specificity": "Patients with chronic kidney disease (anemia treatment context).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:44.663360+00:00"}
{"study_id": 13050, "supplement_id": 1111, "safety_score": "50", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether fixed low-dose ESA therapy compared to high-dose ESA therapy affects patient outcomes, including serum parameters, mortality, cardiovascular events, and quality of life in hemodialysis patients.", "results_summary": "The study found inconclusive effects of fixed low-dose ESA therapy on serum parameters (ferritin, transferrin, albumin, C-reactive protein) and no significant impact on mortality, cardiovascular events, or quality of life. The trial was terminated early due to convergence of ESA doses between groups.", "population_specificity": "Hemodialysis patients over 18 years with anemia or receiving ESA treatment in Italy.", "effective_dosage": "Fixed low dose (4000 IU epoetin alfa equivalent weekly) or high dose (18,000 IU epoetin alfa equivalent weekly).", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:45.553967+00:00"}
{"study_id": 13052, "supplement_id": 1111, "safety_score": "60", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to review the historical changes in hemoglobin-targeted anemia therapy using Erythropoiesis-Stimulating Agents (ESAs) from 1989 to the present, including safety, efficacy, and evolving treatment guidelines.", "results_summary": "Initial studies supported improvements in cardiovascular and organ function as well as quality of life with ESA therapy, but later randomized controlled trials raised safety concerns about robust anemia correction, leading to decreased ESA utilization and revised hemoglobin targets. The study also notes the slower evolution of ferritin-targeted iron administration.", "population_specificity": "Patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:48.241724+00:00"}
{"study_id": 13055, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether using erythropoiesis-stimulating agents (ESAs) to correct anemia before dialysis could reduce early-phase coronary events after hemodialysis initiation.", "results_summary": "The study found that ESA use was associated with lower coronary event rates, particularly in patients with hemoglobin \u22658.5 g/dl. Nonuse of ESA and diabetes mellitus were significant predictors of coronary events.", "population_specificity": "242 patients with chronic kidney disease initiating maintenance hemodialysis, excluding those with prior blood transfusions or cardiovascular events.", "effective_dosage": "Not specified", "study_duration": "Follow-up for 1 year after hemodialysis initiation", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:48.512749+00:00"}
{"study_id": 13053, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether Erythropoiesis-Stimulating Agents (ESAs) provide reno-protective benefits in renal patients, including those at high risk of AKI, kidney transplant recipients, and chronic kidney disease patients.", "results_summary": "Meta-analyses of clinical trials showed no statistically significant improvement in renal outcomes with ESA treatment, including no reduction in AKI incidence, delayed graft function, or CKD progression. Trends favored ESA-treated arms but lacked clinical significance.", "population_specificity": "Renal patients (high-risk AKI, kidney transplant recipients, chronic kidney disease predialysis patients).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:48.919427+00:00"}
{"study_id": 13054, "supplement_id": 1111, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to identify predictors of response to Erythropoiesis-Stimulating Agents (ESAs) in myelofibrosis patients with severe anemia and assess their safety and efficacy.", "results_summary": "Anemia response was achieved in 53% of patients, with a median duration of 19.3 months. Female sex, leukocyte count \u226510\u00d7109/L, and serum ferritin <200 ng/mL were associated with higher response rates, while thrombotic complications occurred at a rate of 2.41 events per 100 patient-years.", "population_specificity": "163 myelofibrosis patients with severe anemia, mostly with inadequate erythropoietin levels (<125 U/L).", "effective_dosage": "Not specified", "study_duration": "Median response duration was 19.3 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:49.589072+00:00"}
{"study_id": 13056, "supplement_id": 1111, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to determine whether long-acting erythropoiesis-stimulating agents (DA and CERA) effectively prevent the progression of anemia at the initiation of dialysis in CKD patients.", "results_summary": "Both DA and CERA maintained hemoglobin levels around 10 g/dL before dialysis but significantly decreased to ~9 g/dL at dialysis initiation. CERA required fewer injections than DA, suggesting potential advantages in reducing administration frequency.", "population_specificity": "40 CKD patients treated with DA and 15 CKD patients treated with CERA.", "effective_dosage": "Not specified (total doses were similar between groups).", "study_duration": "6 months before dialysis initiation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:49:50.190451+00:00"}
